<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="ppub"/></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS189452</article-id><article-id pub-id-type="doi">10.1101/2023.10.06.561265</article-id><article-id pub-id-type="archive">PPR738962</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">4</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Whole blood transcriptional profiles and the pathogenesis of tuberculous meningitis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hai</surname><given-names>Hoang Thanh</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="fn" rid="FN1">*</xref></contrib><contrib contrib-type="author"><name><surname>Nhat</surname><given-names>Le Thanh Hoang</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="fn" rid="FN1">*</xref></contrib><contrib contrib-type="author"><name><surname>Tram</surname><given-names>Trinh Thi Bich</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Vinh</surname><given-names>Do Dinh</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Nath</surname><given-names>Artika P</given-names></name><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Donovan</surname><given-names>Joseph</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Thu</surname><given-names>Nguyen Thi Anh</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Van Thanh</surname><given-names>Dang</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bang</surname><given-names>Nguyen Duc</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Minh Ha</surname><given-names>Dang Thi</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Phu</surname><given-names>Nguyen Hoan</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Nghia</surname><given-names>Ho Dang Trung</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Van</surname><given-names>Le Hong</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Inouye</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="A6">6</xref><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Thwaites</surname><given-names>Guy E</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Thuong</surname><given-names>Nguyen Thuy Thuong</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A5">5</xref><xref ref-type="corresp" rid="CR1">#</xref></contrib><aff id="A1"><label>1</label>Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam</aff><aff id="A2"><label>2</label>Pham Ngoc Thanh Hospital, Ho Chi Minh City, Viet Nam</aff><aff id="A3"><label>3</label>Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam</aff><aff id="A4"><label>4</label>Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Viet Nam</aff><aff id="A5"><label>5</label>Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, United Kingdom</aff><aff id="A6"><label>6</label>Cambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia</aff><aff id="A7"><label>7</label>Cambridge Baker Systems Genomics Initiative, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom</aff></contrib-group><author-notes><fn id="FN1" fn-type="equal"><label>*</label><p id="P1">equal contribution</p></fn><corresp id="CR1"><label>#</label>corresponding author</corresp></author-notes><pub-date pub-type="nihms-submitted"><day>12</day><month>10</month><year>2023</year></pub-date><pub-date pub-type="preprint"><day>10</day><month>10</month><year>2023</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0 International license</ext-link>.</license-p></license></permissions><abstract><sec id="S1"><title>Background</title><p id="P2">Mortality and morbidity from tuberculous meningitis (TBM) are frequent and strongly associated with the inflammatory response to <italic>Mycobacterium tuberculosis</italic> infection. However, the mechanisms driving the associations are uncertain. We sought to identify the gene modules, hubs and pathways associated with the pathogenesis and mortality from TBM, and to identify which best-predicted death.</p></sec><sec id="S2"><title>Methods</title><p id="P3">We used whole blood RNA sequencing to obtain transcriptional profiles from 281 Vietnamese adults with TBM (207 HIV-negative; 74 HIV-positive), 295 with pulmonary TB (PTB), and 30 healthy controls. The TBM cohort was divided randomly into a discovery cohort (n=142) and a validation cohort (n=139). Weighted gene co-expression network analysis identified clusters of genes (or ‘modules’) and hub genes associated with death or disease severity. An overrepresentation analysis identified pathways associated with TBM mortality, with a consensus analysis identifying consensual patterns between HIV-positive and HIV-negative individuals. A multivariate elastic-net Cox regression model selected the candidate predictors of TBM mortality, then model prediction performance using logistic regression and internal bootstrap validation to choose best predictors.</p></sec><sec id="S3"><title>Results</title><p id="P4">Overall, TBM mortality was associated with increased neutrophil activation and decreased T and B cell activation pathways. Death from TBM was associated with increased angiogenesis in HIV-positive adults, and with activated TNF signaling and down-regulated extracellular matrix organization in HIV-negative adults. PTB and TBM have similar transcriptional profiles compared to healthy controls, although inflammatory genes were more activated in HIV-positive than HIV-negative TBM. The expression of four hub genes – <italic>MCEMP1, NELL2, ZNF354C</italic> and <italic>CD4</italic> – were strongly predictive of death from TBM (AUC 0.80 and 0.86 for HIV-negative and HIV-positive, respectively).</p></sec><sec id="S4"><title>Conclusions</title><p id="P5">Whole blood transcriptional profiling revealed that TBM is associated with a characteristic systemic inflammatory response, similar to that invoked by pulmonary tuberculosis, but with key gene modules, hubs and pathways strongly associated with death. Our analysis suggests a novel 4-gene biomarker for predicting death from TBM, but also opens a new window into TBM pathogenesis that may reveal novel therapeutic targets for this lethal disease.</p></sec></abstract><kwd-group><kwd>tuberculosis meningitis</kwd><kwd>mortality</kwd><kwd>prognostic</kwd><kwd>RNA sequencing</kwd><kwd>gene expression</kwd><kwd>weighted gene co-expression network analysis</kwd></kwd-group></article-meta></front><body><sec id="S5" sec-type="intro"><title>Introduction</title><p id="P6">Of 7.1 million new tuberculosis (TB) cases in 2019, tuberculous meningitis (TBM) is estimated to have developed in 164,000 adults, around 25% of whom were living with HIV <sup><xref ref-type="bibr" rid="R1">1</xref></sup>. TBM is the most severe form of TB, causing death or neurological disability in half of all cases. Overall, TBM mortality is around 25%, but rises to around 50% in those with HIV, with most deaths occurring in the first 3 months of treatment <sup><xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R2">2</xref></sup>.</p><p id="P7">The poor outcomes from TBM are strongly associated with the inflammatory response <sup><xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R4">4</xref></sup>, with both a paucity and an excess of inflammation linked to death from TBM <sup><xref ref-type="bibr" rid="R5">5</xref>–<xref ref-type="bibr" rid="R11">11</xref></sup>. However, the mechanisms behind these observations remain uncertain. Immune responses in TBM are thought to be compartmentalized within the central nervous system. Studies have shown that immune cell counts, cytokine concentrations, metabolites and transcriptional responses differ between the peripheral blood and the cerebrospinal fluid (CSF) <sup><xref ref-type="bibr" rid="R10">10</xref>,<xref ref-type="bibr" rid="R12">12</xref>,<xref ref-type="bibr" rid="R13">13</xref></sup>. In adults with TBM, leukocyte activation is higher in the CSF than in peripheral blood, although a marked myeloid response in peripheral blood has been reported <sup><xref ref-type="bibr" rid="R10">10</xref></sup>. Blood transcriptomic analysis has found increased neutrophil-associated transcripts and inflammasome signaling in those with HIV-associated TBM and immune reconstitution inflammatory syndrome <sup><xref ref-type="bibr" rid="R5">5</xref></sup>. In children with TBM, whole blood transcriptional profiles showed increased inflammasome activation and decreased T-cell activation <sup><xref ref-type="bibr" rid="R12">12</xref></sup>. Taken together, these studies suggest the inflammatory response associated with TBM may have a greater systemic component than originally thought and its characterization may help define the immune mechanisms leading to death and disability.</p><p id="P8">The accurate and early detection of patients at highest risk of complications and death from TBM may help to target treatment for those most in need. The British Medical Research Council (MRC) grades have been used to categorize TBM severity for almost 80 years <sup><xref ref-type="bibr" rid="R14">14</xref></sup>, and the system strongly predicts TBM mortality <sup><xref ref-type="bibr" rid="R15">15</xref></sup>. Previously, we and others developed new prognostic models from studies of 1699 adults with TBM using clinical and laboratory parameters, including MRC grade <sup><xref ref-type="bibr" rid="R4">4</xref>,<xref ref-type="bibr" rid="R15">15</xref></sup>. These models predicted outcome more accurately than MRC grade alone. However, they might be improved by measures of host inflammatory response. Host-based peripheral blood gene expression analysis has been used to identify active or progressive pulmonary TB and in pulmonary TB treatment monitoring <sup><xref ref-type="bibr" rid="R16">16</xref>,<xref ref-type="bibr" rid="R17">17</xref></sup>, but has yet to be applied to TBM.</p><p id="P9">In the current study, we investigated whole blood RNA sequencing (RNA-seq) transcriptional profiles in 281 Vietnamese adults with TBM, 295 with pulmonary TB (PTB), and 30 healthy controls. Our objective was to use weighted gene co-expression network analysis, an unbiased and well-evaluated approach, to identify the biological pathways and hub genes associated with TBM pathogenesis and assess the predictive value of gene expression for early mortality from TBM.</p></sec><sec id="S6" sec-type="results"><title>Results</title><sec id="S7"><title>Characteristics and outcomes of the cohorts</title><p id="P10">Four RNA-seq cohorts (all ≥18 years) were used in the study, representing a total of 606 participants. The characteristics of these cohorts are provided in <xref ref-type="table" rid="T1">Table 1</xref>. There were 281 adults with TBM; 207 HIV-negative and 74 HIV-positive. In the HIV-negative TBM adults, the median age was 46 years (IQR 34, 58), 127 (61%) were male, and the median Body Mass Index (BMI) was 20.0 (IQR 18.2, 22.3). HIV-positive TBM were more likely than HIV-negative TBM to be male, younger, have lower BMI, have previously received TB treatment, and to have microbiologically confirmed TBM. Total white cell counts in blood and CSF in HIV-positive TBM were lower than in HIV-negative TBM. Median CD4 cell counts in HIV-positive TBM were 67 cells/mm<sup>3</sup> (IQR 19, 124) and 28 (39%) were receiving antiretroviral therapy. The PTB cohort consisted of 295 HIV-negative adults with the median age of 44 years (IQR 31, 52), 228 (77%) were male, the median of BMI was 19.4 (IQR 17.7, 21.6) and 129 (48%) had pulmonary cavities on chest X-ray. Of the 30 healthy controls, 11 (37%) were male, and the median age was 33 (IQR 29, 37). In real-time quantitative polymerase chain reaction (qPCR) validation cohort, 132 HIV-negative TBM adults have similar characteristics as HIV-negative TBM RNA-seq cohort (<xref ref-type="table" rid="T1">Table 1</xref>).</p><p id="P11">The clinical variables associated with three-month mortality of the 281 adults with TBM in RNA-seq cohort are given in <xref ref-type="table" rid="T2">Table 2</xref>. The discovery (n=142) and validation (n=139) cohorts had similar characteristics (<xref ref-type="table" rid="T2">Table 2</xref>). 47.5% (133/280) had definite TBM <sup><xref ref-type="bibr" rid="R18">18</xref></sup>, with microbiologically confirmed disease, accounting for 45.9% (101/220) of survivors and 52.4% (32/61) of those who died. The overall three-month mortality rate was 21.7% (61/281) for TBM regardless of HIV status: 16.4% (34/207) in HIV-negative and 36.5% (27/74) in HIV-positive (p&lt;0.001). We did not observe differences in mortality by sex, age and diagnostic category. Greater disease severity, MRC grades 2 and 3 at enrolment, was associated with increased mortality compared to grade 1 (p&lt;0.001). In those who died, CSF and peripheral blood neutrophil counts were higher and peripheral blood lymphocyte count lower, compared to those who survived.</p><p id="P12">In the qPCR validation cohort (n=132), three-month mortality rate was 28.8% (38/132) and those who died were of older age, had more severe disease, and had lower number of CSF leukocytes and lymphocytes (<xref ref-type="supplementary-material" rid="SD1">Table S1</xref>). Death was not associated with CSF or peripheral blood neutrophil counts.</p></sec><sec id="S8"><title>Whole blood transcriptional profiles of the four RNA-seq cohorts</title><p id="P13">We analyzed the whole blood transcriptomics, using bulk RNA sequencing from 606 participants in the 4 cohorts. On average 35.1 million reads/sample were obtained with 89.4% reads mapping accuracy to human reference genome (GRCh.38 release 99) and 65.4% of reads were uniquely mapped. The study objectives and cohorts flow are presented in <xref ref-type="fig" rid="F1">Figure 1</xref>. Principal component analysis on the transcriptomic data of 20,000 genes across 4 studies showed different profiles between healthy controls from both PTB and TBM cases (<xref ref-type="fig" rid="F2">Figure 2</xref>). The PTB profile substantively overlapped with TBM, with some separation between HIV-negative and HIV-positive TBM (<xref ref-type="fig" rid="F2">Figure 2</xref>).</p><p id="P14">Enrichment scores from single sample gene set enrichment analysis (ssGSEA), which based on expression rank of genes relevant to pathways, were measured in some pathways already known to be important mediators of TB or TBM pathogenesis (<xref ref-type="fig" rid="F2">Figure 2</xref>). As anticipated, inflammatory response, cytokine signaling, interferon signaling, TNF signaling, and inflammasome activation pathways, were enriched in PTB and TBM cohorts as compared to healthy controls. In TBM, enrichment of genes in these pathways were generally higher in HIV-positive than in HIV-negative individuals (<xref ref-type="supplementary-material" rid="SD1">Tables S2</xref>, <xref ref-type="supplementary-material" rid="SD1">S6</xref>).</p></sec><sec id="S9"><title>Transcriptional gene modules associated with TBM severity and mortality</title><p id="P15">Transcriptional profiles associated with TBM mortality were generated by identifying differentially expressed genes. Of the top 20,000 genes with most variation, we observed 724 (3.6%) genes that were differentially expressed (FDR &lt;0.05, absolute fold change (FC) &gt;1.5) in all those with TBM (<xref ref-type="fig" rid="F3">Figure 3</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S3</xref>). Next, we applied weighted gene co-expression network analysis (WGCNA) to 5000 most variable genes from 281 TBM samples (n= 207, HIV-negative; n=74, HIV-positive) to define clusters of highly correlated genes (modules) associated with TBM severity and mortality. Gene modules are clusters of genes that have highly interconnected expression, usually related to their biological functions. Hub genes are genes with high connectivity to other genes within a respective module. First, we used WGCNA to construct a network of gene modules in the discovery cohort. Then we validated the presence of these transcriptional modules in the validation cohort, labelling the modules with different colors. In the discovery cohort (n=142), 15 modules were identified overall, consisting of 44 to 1350 genes per module (<xref ref-type="supplementary-material" rid="SD1">Figure S1</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S7</xref>). All 15 modules were preserved in the validation cohort (n=139) through the preservation analysis (<xref ref-type="supplementary-material" rid="SD1">Figure S2</xref>).</p><p id="P16">The associations between the 15 modules and TBM severity and mortality are presented in <xref ref-type="fig" rid="F4">Figure 4</xref> for both the discovery and validation cohorts. Modules were linked to each other in a hierarchical structure, with major biological processes annotated. Associations of the modules with TBM disease severity (MRC grade) at baseline were estimated by Spearman correlations between MRC grade and the first principle component (PC1) of each module. Similarly, associations of the modules with mortality were measured by hazard ratio (HR) per increase 1 unit of PC1 using Cox regression model adjusted for age, HIV status and dexamethasone treatment (<xref ref-type="fig" rid="F4">Figure 4</xref>) in both discovery and validation cohorts.</p><p id="P17">Of the 15 preserved modules, five modules were significantly associated with mortality in the discovery and validation cohorts, with false discovery rate (FDR) &lt; 0.05 (<xref ref-type="fig" rid="F4">Figure 4</xref>). These five modules were separated into two big module clusters. The first cluster contained the blue module (n=799 genes), involved in inflammatory and innate immune responses, and the cyan module (n=44 genes) with unknown biological function. These modules were upregulated in those who died, as shown in the heat-map in <xref ref-type="fig" rid="F4">Figure 4</xref> (HR: 3.0 and 2.2 for the blue module, and 2.1 and 1.7 for the cyan module, FDR &lt; 0.05 for all comparisons). The black (n= 207 genes), brown (n=698 genes) and red (n=229 genes) modules were in the second cluster and were generally involved in adaptive immunity including T and B cell signaling pathways. These three modules were down-regulated in those who died (HR: 0.43 and 0.36 for brown, 0.46 and 0.39 for red, 0.59 and 0.49 for black) (<xref ref-type="fig" rid="F4">Figure 4</xref>).</p><p id="P18">It is known that TBM MRC grade before treatment initiation strongly predicts outcome from TBM. Here, we investigated correlations between each module and MRC grade and their association with mortality.</p><p id="P19">The pink module, involved in hemostasis and platelet activation, was positively correlated with MRC grade, but not mortality. Of the five modules associated with death from TBM, all were correlated with MRC grade (<xref ref-type="fig" rid="F4">Figure 4</xref>). Four of these five modules, were enriched for immune responses.</p></sec><sec id="S10"><title>Transcriptional hub genes associated with TBM severity and mortality</title><p id="P20">We next identified hub genes within the four biologically functional modules associated with TBM mortality in both the discovery and validation cohorts. Hub genes showed higher connectivity within the modules, and stronger association with TBM mortality as compared to less connected genes within a module (<xref ref-type="supplementary-material" rid="SD1">Figure S3</xref>). Seven hub genes (<italic>ETS2, PGD, UPP1, CYSTM1, FCAR, KIF1B</italic> and <italic>MCEMP1</italic>) were upregulated in death, all from the acute inflammation (blue) module. Hub genes from the brown, red and black modules were downregulated in death and were involved in adaptive immune response. Ten hub genes associated with mortality (<italic>CD96, TNFRSF25, TBC1D4, CD28, ABLIM1, RASGRP1, NELL2, TRAF5, TESPA1, TRABD2A</italic>) were from the brown module, three (<italic>EVL, PLCG1, NLRC3</italic>) from the red, and six (<italic>CD2, CD247, TGFBR3, ARL4C, KLRK1, MATK</italic>) from the black module (<xref ref-type="fig" rid="F5">Figure 5</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S8</xref>). For qPCR validation, available samples from HIV-negative TBM patients (n=132) were used to evaluate 11 hub genes selected from the blue and brown modules. 8/11 hub genes were found to be significantly associated with mortality, as determined by univariate Cox regression (<xref ref-type="table" rid="T3">Table 3</xref>). Three genes (FCAR, PGD, ETS2) were also found to be associated with mortality, but in the reverse direction.</p><p id="P21">We next examined patterns of shared and distinct gene expression of some hub across the four cohorts (healthy controls, PTB, and TBM with and without HIV-infection) to reveal disease progression and pathogenesis of different TB forms (<xref ref-type="fig" rid="F6">Figure 6</xref>). There were two upregulated genes from the acute inflammation module (<italic>FCAR</italic> and <italic>MCEMP1</italic>) and six downregulated genes (<italic>NELL2, TRABD2A, PLCG1, NLRC3, CD247</italic> and <italic>MATK</italic>) from the other three adaptive immunity modules. The patterns of up and downregulation, relative to healthy controls, were similar in PTB and TBM, although tended to be more pronounced in those with TBM as well as those with HIV (<xref ref-type="fig" rid="F6">Figure 6</xref>).</p></sec><sec id="S11"><title>Transcriptional immune pathways associated with TBM mortality</title><p id="P22">To better understand the biological functions of the five modules associated with TBM mortality, a gene set associated with mortality in each module was functionally annotated using known pathway databases, such as gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) <sup><xref ref-type="bibr" rid="R19">19</xref></sup>. Pathway enrichment analysis was performed using fold enrichment to determine if the prevalence of genes in a pathway were different from that expected by chance. We also used ssGSEA enrichment scores based on gene expression ranking of genes in a particular pathway within a single individual, to show the activity of this pathway between death and survival TBM as well as across 4 cohorts. These analyses helped to identify the pathways linked to mortality within the gene modules.</p><p id="P23">In the blue module, we found TBM mortality was associated with upregulated inflammatory and innate immune response transcripts, particularly in pathways involved in the acute inflammatory response and the regulation of inflammatory responses, including responses to bacteria and neutrophil activation. KEGG pathway analysis suggested this signal was associated with transduction and immune system pathways, such as toll-like receptor signaling, TNF signaling, NF-kappa B signaling and neutrophil extracellular trap formation (<xref ref-type="fig" rid="F5">Figure 5</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S9</xref>).</p><p id="P24">We did not find any pathway significantly associated with mortality in the upregulated cyan gene module, although in the hierarchical clustering the cyan module was highly correlated with the blue - inflammatory response module (<xref ref-type="fig" rid="F4">Figure 4</xref>). In contrast, analyses of the down-regulated brown, red and black modules highlighted pathways involved in adaptive immunity, predominantly those mediated by lymphocytes. These included downregulations of lymphocyte proliferation, T cell activation, B cell activation, natural killer cell mediated cytotoxicity and their signaling pathways such as antigen receptor-mediated, T and B cell receptor (<xref ref-type="fig" rid="F5">Figure 5</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S9</xref>).</p><p id="P25">We also investigated the association between pathways known to be important to TB pathogenesis and mortality (<xref ref-type="fig" rid="F7">Figure 7</xref>). Looking at those who died vs. survived amongst HIV-positive TBM, there was little difference between the groups with respect to inflammatory response, cytokine signaling, and icosanoid and inflammasome activation. This was also the case for HIV-negative individuals. However, interferon and TNF pathways were more active in those with HIV, and TNF signaling expression was significantly higher in HIV-negative adults who died rather than survived.</p></sec><sec id="S12"><title>HIV influence on modules, hub genes, and pathways associated with TBM mortality</title><p id="P26">Transcriptional profiles associated with TBM mortality stratified by HIV status are shown in <xref ref-type="fig" rid="F3">Figure 3</xref>. In HIV-negative individuals, 786 (3.9%) genes were differentially expressed, whereas in HIV-positive the number was 1620 (8.1%) genes (<xref ref-type="fig" rid="F3">Figure 3</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S3 &amp; S4</xref>). We hypothesized that host transcriptional signatures associated with TBM mortality differ according to HIV status. To test this hypothesis, we constructed gene co-expression networks from all genes in HIV-negative (n=207) and HIV-positive (n=74) individuals separately, then performed consensus gene co-expression network analysis (<xref ref-type="supplementary-material" rid="SD1">Figure S4</xref>). Modules were identified with colors and to discriminate them from the modules linked to mortality alone we added an annotated function on the module name. We focused on modules that failed to form consensus associations with mortality due to opposite associations in the two cohorts.</p><p id="P27">Sixteen gene co-expression modules (<xref ref-type="fig" rid="F8">Figure 8</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S10</xref>), ranging from 60 to 958 genes, were obtained from the HIV-negative and positive cohorts. Of these, 12 modules formed consensus association with mortality (<xref ref-type="fig" rid="F8">Figure 8</xref>). Of the 4 modules which failed to form consensus association, two modules were significantly associated with mortality (FDR&lt;0.05). The blue-angiogenesis module was up-regulated in death in HIV-positive adults (HR: 1.7) and the yellow-extracellular matrix organization (EMO) module was down-regulated in death in HIV-negative adults (HR: 0.31) (<xref ref-type="fig" rid="F8">Figure 8</xref>).</p><p id="P28">Hub genes associated with mortality, which are highly correlated with other genes in the module, were identified in the two modules. Five hub genes, with three downregulated (<italic>ZNF354C, ZNF721</italic> and <italic>ETAA1</italic>) and two upregulated (<italic>CEP295NL</italic> and <italic>RNF24</italic>), were identified in the blue-angiogenesis module. Other five hub genes, with four downregulated (<italic>IL11RA, CD4, ZNF395</italic> and <italic>BCL9L</italic>) and one upregulated (<italic>PPP4R2</italic>), were identified in the yellow-EMO module (<xref ref-type="fig" rid="F8">Figure 8</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S11</xref>). Expression of some hub genes across the four cohorts showed the patterns of up (<italic>RNF24</italic>) and downregulation (<italic>ZNF721, BCL9L</italic> and <italic>IL11RA</italic>), and relative to healthy controls they were similar in PTB and TBM. Expression of <italic>RNF24</italic> and <italic>ZNF721</italic> genes were significantly associated with death in HIV-positive adults, whereas expression of <italic>BCL9L</italic> and <italic>IL11RA</italic> genes were significantly associated with death in HIV-negative adults (<xref ref-type="supplementary-material" rid="SD1">Figure S5</xref>).</p><p id="P29">Pathway enrichment analysis showed genes in the blue-angiogenesis module were significantly enriched for angiogenesis or blood vessel development, leukocyte and neutrophil activation, and signal transduction pathways (<xref ref-type="fig" rid="F8">Figure 8</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S12</xref>). Gene expression in the yellow-module was strongly enriched in extracellular matrix organization, cell-substrate adhesion and protein localization pathways (<xref ref-type="fig" rid="F8">Figure 8</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S12</xref>). Hierarchical clustering of modules indicated that these two modules were highly correlated (<xref ref-type="fig" rid="F8">Figure 8</xref>) suggesting they share similar functions, which appeared in some pathways such as angiogenesis and extracellular matrix organization.</p><p id="P30">In addition, almost all of the pathways significantly associated with TBM mortality were similar in HIV-negative and positive cohorts, confirming that these important pathways were common to all TBM (<xref ref-type="supplementary-material" rid="SD1">Figure S6</xref>). However, pathway enrichment scores were higher in HIV-positive than in HIV-negative, especially for the TNF signaling pathway and TNF transcripts (<xref ref-type="fig" rid="F9">Figure 9</xref>). Death in HIV-negative TBM was associated with increased enrichment of these pathways, but with less TNF transcript compared to HIV-positive individuals. The enrichment scores indicated mortality was strongly associated with downregulation of adaptive immune responses, including T cell activation, T and B cell receptor signaling pathways, with little impact of HIV status on these pathways (<xref ref-type="fig" rid="F9">Figure 9</xref>). These data suggest an inadequate adaptive immune response contributes to disease pathogenesis and mortality in all those with TBM, regardless of HIV status.</p></sec><sec id="S13"><title>Predictors of TBM mortality</title><p id="P31">We aimed to identify baseline gene signatures that might help predict death or survival from TBM. We selected potential gene predictors from 26 common and 10 HIV-specific hub genes; these hub genes represented the dominant modules associated with mortality. Three predefined clinical factors known to be associated with outcome (age, MRC grade and CSF lymphocytes) were also used for candidate predictor selection. Using a multivariate Cox elastic-net regression model for 39 predictors, six predictors were selected for HIV-negative TBM (MRC grade, age, CSF lymphocyte count, gene set 1: <italic>MCEMP1, TRABD2A</italic> and <italic>CD4</italic>), and six predictors were selected for HIV-positive TBM (MRC grade, age, CSF lymphocyte count, gene set 2: <italic>NELL2, MCEMP1</italic> and <italic>ZNF354C</italic>) (<xref ref-type="supplementary-material" rid="SD1">Table S13</xref>).</p><p id="P32">Gene expression and association with mortality of five distinct genes in gene sets 1 and 2 were presented in <xref ref-type="supplementary-material" rid="SD1">Figure S7</xref>. By combining the two gene sets above and reducing genes in the same module, we generated gene set 3 (<italic>MCEMP1, TRABD2A, CD4</italic> and <italic>ZNF354C</italic>) and gene set 4 (<italic>MCEMP1, NELL2, ZNF354C</italic> and <italic>CD4</italic>). These two gene sets, with and without clinical factors (age, MRC grade and CSF lymphocytes), were tested for their predictive performance in HIV-negative and HIV-positive RNA-seq cohorts together with a reference model <sup><xref ref-type="bibr" rid="R15">15</xref></sup>. Model 7 using gene set 4 and clinical factors outperformed other gene sets and reference model, with the best overall model performance (lowest optimism-corrected Brier score, 0.11 and 0.14 for HIV-negative and HIV-positive, respectively) and the best discriminant performance (highest optimism-corrected AUC 0.80 and 0.86 for HIV-negative and positive) (<xref ref-type="table" rid="T4">Table 4</xref>, <xref ref-type="supplementary-material" rid="SD1">Figure S8</xref>).</p><p id="P33">Given that gene expression could reflect cellular composition changes of the peripheral blood, with neutrophils being the most abundant sub-population, we performed a sensitivity analysis including blood neutrophil count as a potential gene predictor in a multivariate Cox elastic-net regression model. In the sensitivity analysis, all six predictors for either HIV-negative TBM or HIV-positive TBM were repeatedly selected (<xref ref-type="supplementary-material" rid="SD1">Table S14</xref>). We evaluated the predictive values of blood neutrophil alone and in combination with identified gene sets, but adding neutrophils did not improve the overall performance of the predictive models.</p><p id="P34">Next, we evaluated the prognostic signature of model 7 in another sample set of 132 HIV-negative TBM patients with gene expressions measured by qPCR. Only three genes (<italic>MCEMP1, NELL2</italic> and <italic>ZNF354C</italic>) from gene set 4 were used because qPCR data of <italic>CD4</italic> was not available. The analysis demonstrated good predictive performance in model 8, with an optimism-corrected AUC 0.92 and optimism-corrected Brier score 0.12 (<xref ref-type="table" rid="T4">Table 4</xref>, <xref ref-type="supplementary-material" rid="SD1">Figure S8</xref>). Despite using three-gene signature in the validation, the results still confirmed the ability to predict TBM mortality in HIV-negative patients.</p></sec></sec><sec id="S14" sec-type="discussion"><title>Discussion</title><p id="P35">The biological pathways involved in pathogenesis of TBM are unclear. In general, previous studies investigating TBM pathogenesis have been small, testing for relatively small numbers of selected genes or molecules, and have been unable to take an unbiased and broader view of the inflammatory response. This study investigated the pathways associated with death from TBM at a whole-genome transcriptome level in whole blood, characterizing a global dysregulation in immune responses, including inflammation, and revealing specific functional pathways and hub genes involved in TBM and the mechanisms leading to death.</p><p id="P36">We sought to understand better the pathogenesis of TBM by identifying pretreatment blood transcriptional gene modules associated TBM disease severity and three-month mortality. Four out of five identified modules were involved in immunological functions, indicating multiple functional pathways of systemic immunity are involved in the pathogenesis of TBM. In particular, mortality was strongly associated with increased acute inflammation and neutrophil activation, and decreased adaptive immunity and T and B cell activation. Whilst there appeared to be many common pathways involved in TBM mortality in HIV-positive and negative individuals, there were differences: death was associated with increased expression of angiogenesis genes in HIV-positive adults, and with TNF signaling and down regulated extracellular matrix organization in HIV-negative adults. We also identified a four-gene signature as a potential host response biomarker for mortality, regardless of HIV status.</p><p id="P37">TBM mortality was associated with increased acute inflammatory responses, the regulation of inflammatory responses, and neutrophil activation. Previous blood transcriptome studies have shown that IFN-inducible neutrophil-driven transcripts were over-expressed in blood neutrophils from active TB patients compared to those with latent TB <sup><xref ref-type="bibr" rid="R20">20</xref>,<xref ref-type="bibr" rid="R21">21</xref></sup>. Another study described that TBM adults who developed IRIS during treatment, also had significantly more abundant neutrophil-associated transcripts that preceded the development of TBM-IRIS <sup><xref ref-type="bibr" rid="R5">5</xref></sup>. Our own earlier studies have also suggested a role for neutrophils in TBM pathogenesis, with high pretreatment CSF bacterial loads being correlated with high neutrophil numbers in both CSF and blood and more frequent new neurological events or paradoxical inflammatory complications <sup><xref ref-type="bibr" rid="R8">8</xref></sup>.</p><p id="P38">Taken together with previous studies, our findings support an important role for over-activation of neutrophil-mediated inflammatory responses in TBM pathogenesis and its lethal complications. Looking further into specific pathways, TBM mortality was neither associated with inflammatory response and cytokine signaling pathways in general, nor with interferon or inflammasome activation. However, increased transcripts in some specific immunity pathways, including TNF signaling, Toll-like receptor, NF-kappa B and neutrophil extracellular trap formation, were associated with TBM mortality. These pathways are involved as activators or effectors in the process of neutrophil activation and regulation, leading to an exacerbated inflammatory response <sup><xref ref-type="bibr" rid="R22">22</xref>–<xref ref-type="bibr" rid="R24">24</xref></sup>.</p><p id="P39">We found blood transcriptional responses of T cells and B cells were under-expressed in those who died from TBM, indicating an impairment in adaptive immunity in fatal disease. A reduction of activities in both T cell and B cell receptor signaling pathways in death were identified, independent of over-expression of neutrophil-mediated immune responses, indicating that multiple functional pathways influence TBM mortality. TBM pathogenesis is known to be associated with T cell impairment. Previous studies have shown lower numbers of T cells, reduced ability to respond to <italic>Mycobacterium tuberculosis</italic> antigens or reduced expression of activation markers and cytokine production in TBM compared to PTB and healthy individuals <sup><xref ref-type="bibr" rid="R10">10</xref>,<xref ref-type="bibr" rid="R25">25</xref>,<xref ref-type="bibr" rid="R26">26</xref></sup>. This impaired T cell function has correlated with disease severity and poor clinical outcomes in participants with PTB and TBM <sup><xref ref-type="bibr" rid="R10">10</xref>,<xref ref-type="bibr" rid="R27">27</xref>,<xref ref-type="bibr" rid="R28">28</xref></sup>.</p><p id="P40">B cells and antibodies also influence humoral immunity against <italic>Mycobacterium tuberculosis</italic>. Studies have shown a decreased memory B cell proportion, and lower levels of IgG, IgM antibodies and Fcγ receptors binding capacity in plasma in those with active lung TB compared to those with latent TB or healthy volunteers <sup><xref ref-type="bibr" rid="R29">29</xref>,<xref ref-type="bibr" rid="R30">30</xref></sup>. But little is known about the role of B cells in TBM. The observed association between TBM mortality and decreased transcriptional responses in B cell activation and B cell receptor signaling pathways suggest an unanticipated role for B cells and humoral immunity in TBM pathogenesis that needs further investigation.</p><p id="P41">Transcriptomic profiles from four cohorts, including healthy controls and PTB, provide a broad view of host responses in different TB clinical forms. Our data showed common transcriptional pathways and genes between PTB and TBM. A range of immune responses, involving in inflammation, cytokines, interferon, inflammasome and neutrophil signaling pathways, were activated in both PTB and TBM, but with significantly greater activation in HIV-positive TBM than HIV-negative TBM. This finding aligns with our previous data showing a dyregulated hyper-inflammation in HIV-associated TBM, with significantly higher CSF cytokine concentrations than in those without HIV infection <sup><xref ref-type="bibr" rid="R7">7</xref></sup>. These data suggest that different forms of TB are associated with similar inflammatory responses, but with different degrees of host responses, exemplified by hyper-inflammation in those with HIV.</p><p id="P42">The HIV-driven differences in TBM-associated inflammation appear sufficient to influence response to adjunctive anti-inflammatory therapy with corticosteroids. An earlier randomized controlled trial of corticosteroids in 545 predominantly HIV-negative Vietnamese adults showed they significantly improved survival <sup><xref ref-type="bibr" rid="R31">31</xref></sup>. Our group recently completed a similar sized trial exclusively in HIV-positive adults without any clear benefit upon mortality <sup><xref ref-type="bibr" rid="R32">32</xref></sup>. Therefore, the differences in gene expression associated with TBM mortality in the current study – with angiogenesis activation linked to HIV-positive TBM mortality only, for example – may provide an explanation for the poor response and offer alternative therapeutic strategies. Recent studies have shown that angiogenesis is induced by <italic>Mycobacterium tuberculosis</italic> infection, which then contributes to inflammation, tissue damage and is correlated with disease severity <sup><xref ref-type="bibr" rid="R33">33</xref></sup>.</p><p id="P43">Developing prognostic models for TBM is important for guiding clinical decision making and improving outcomes. Several studies have developed and validated prognostic models for TBM using clinical, laboratory and radiological variables. These models have demonstrated moderate to high accuracy in predicting mortality and functional outcomes from TBM patients <sup><xref ref-type="bibr" rid="R15">15</xref>,<xref ref-type="bibr" rid="R34">34</xref>–<xref ref-type="bibr" rid="R36">36</xref></sup>. In this study, we used blood transcriptional signatures and co-expression network analysis to identify module-representative hub genes. We identified a four-gene set at the start of treatment (<italic>MCEMP1, NELL2, ZNF354C</italic> and <italic>CD4</italic>) whose expression strongly predicted three-month TBM mortality. Our prognostic models combining this four-gene host response in blood and three routine clinical predictors achieved very good performance, with AUC 0.80 and 0.86 for HIV-negative and HIV-positive individuals with TBM, respectively. This is proof-of-concept that whole blood RNA host response might be a useful pre-treatment biomarker to predict early TBM mortality. Although further investigation and validation is needed, we have identified potential gene candidates for future development as prognostic biomarkers.</p><p id="P44">In summary, we present a comprehensive and unbiased analysis of the gene transcripts in blood associated with TBM severity and mortality. Our data open a new window on TBM pathogenesis, with dysregulation in both innate and adaptive immune responses strongly associated with death from TBM. Furthermore, we have identified similarities and differences in the inflammatory responses associated with TBM in HIV-positive and negative adults, which may explain the different therapeutic effects of adjunctive corticosteroid treatment. We also revealed a 4-gene host response signature in blood that might represent a novel biomarker for defining those at highest risk of death, regardless of their HIV status. The signature needs validation in future cohorts.</p></sec><sec id="S15" sec-type="materials | methods"><title>Materials and Methods</title><sec id="S16" sec-type="subjects"><title>Participants</title><p id="P45">We collected data and whole peripheral blood samples for transcriptomic profiling from adults (≥18 years) with TBM enrolled into two randomized controlled trials conducted in Vietnam. The two trials investigated whether adjunctive dexamethasone improves outcome from TBM and the protocols for both trials have been published <sup><xref ref-type="bibr" rid="R37">37</xref>,<xref ref-type="bibr" rid="R38">38</xref></sup>. The ACT-HIV trial (NCT03092817) completed enrolment and follow-up of 520 HIV-positive adults with TBM in April 2023, with the results accepted for publication <sup><xref ref-type="bibr" rid="R32">32</xref></sup>. The LAST-ACT trial (NCT03100786) completed enrollment of 720 HIV-negative adults with TBM in March 2023, with the last participants due to complete follow-up in March 2024.</p><p id="P46">In TBM RNA-seq cohorts, peripheral blood samples were taken from 281 trial participants: the first 207 consecutively enrolled HIV-negative participants from the LAST-ACT trial, and 74 randomly selected HIV-positive participants from the ACT-HIV trial. In qPCR TBM cohorts, 132 HIV-negative participants were randomly selected from remaining participants of LAST-ACT trial with an enrichment for non-survival cases. The samples were taken at enrollment, when patients could not have received more than 6 consecutive days of two or more drugs active against <italic>Mycobacterium tuberculosis</italic>. All trial participants then received standard 4-drug anti-tuberculosis treatment for 2 months, followed by 3 drugs for 10 months, and were randomly allocated to dexamethasone or identical placebo for the first 6-8 weeks <sup><xref ref-type="bibr" rid="R37">37</xref>,<xref ref-type="bibr" rid="R38">38</xref></sup>. The investigators remain blind to the treatment allocation until the last participant completes follow-up and the database has been locked. Therefore, an analysis of the direct influence of corticosteroids on inflammatory response and outcome is not included in the current study. To adjust for corticosteroid effect, treatment outcome and effect were blinded in analyses by extracting only the fold change difference between survival and death in the linear regression model, in which gene expression was outcome and survival and treatment were covariates.</p><p id="P47">Peripheral blood samples were taken for transcriptional profiling from two other cohorts: 295 adults with PTB and 30 healthy controls. The 295 PTB was enrolled in Pham Ngoc Thach hospital and District TB Units in Ho Chi Minh city, randomly selected from HIV-negative participants from a prospective observational study of the host and bacterial determinants of outcome from PTB (n=900) due to the very low prevalence of HIV in the study population. Participants had culture-confirmed PTB, either drug susceptible TB or a new diagnosis of multidrug-resistant TB. All participants in this cohort had &lt;7 days of anti-TB drugs at enrolment and did not have clinical evidence of extra-pulmonary TB. Healthy controls were enrolled in Hospital for Tropical Diseases in Ho Chi Minh city, from a prospective study for epidemiological characteristics of human resistance to <italic>Mycobacterium tuberculosis</italic> infection. Participants in this cohort were adults without signs or symptoms of TB nor history of TB contact within the last two years.</p><p id="P48">Ethics approval was obtained from the institutional review board at the Hospital for Tropical Diseases, Pham Ngoc Thach Hospital and the ethics committee of the Ministry of Health in Vietnam, and the Oxford Tropical Research Ethics Committee, UK (OxTREC 52-16, 36-16, 24-17, 33-17 and 532-22). All participants provided their written informed consent to take part in the study, or from their relatives if they were incapacitated.</p></sec><sec id="S17"><title>Study design</title><p id="P49">The objectives and cohorts used in this study are presented in <xref ref-type="fig" rid="F1">Figure 1</xref> and a workflow of data analysis is shown in <xref ref-type="supplementary-material" rid="SD1">Figure S10</xref>. Briefly, blood transcriptional profiling was generated from four cohorts of 207 TBM HIV-negative, 74 TBM HIV-positive, 295 PTB and 30 healthy controls. To define transcriptional signatures associated with TBM mortality, data from all 281 TBM participants were used. To ensure reproducibility, in our main analysis we randomly split our TBM data into two datasets, a discovery cohort (n=142) and a validation cohort (n=139). After identifying gene modules associated with mortality, related functional pathways and hub genes were determined with more details of the data analysis provided in <xref ref-type="supplementary-material" rid="SD1">Figure S10</xref>. In a broader view, gene enrichment and expression from significant pathways and hub genes were illustrated across all four cohorts. Next, outcome prediction models were developed for TBM. Finally, the association of hub genes and outcome prediction then was validated in qPCR HIV-negative TBM cohort.</p></sec><sec id="S18"><title>Sample processing and RNA-seq</title><p id="P50">Whole blood samples, collected from participants at enrollment, were stored in PAXgene collection tubes at -80<sup>0</sup>C. RNA extraction and RNA-seq were done in 2 batches. Batch 1 was done in 2020 including 207 HIV-negative TBM, 31 HIV-positive TBM and 295 PTB. Batch 2 was done in 2022 including 43 HIV-positive TBM and 30 Healthy control. RNA samples were isolated using the PAXgene Blood RNA kits (Qiagen, Valencia, CA, USA) following the manufacturer’s instructions, except for an additional washing step before RNA elution. DNA was digested on columns using the RNase-free DNase Set (Qiagen, Valencia, CA, USA). Quality control of the RNA extraction was performed using the Epoch spec for quantity and quality, and Tapestation Eukaryotic RNA Screentape for integrity. Samples with RNA integrity number below 4 were exclude for further steps. RNA-seq was performed by the Ramaciotti Centre for Genomics (Sydney, Australia). One microgram of total RNA was used as input for each sample, using the TruSeq Stranded Total RNA Ribo-zero Globin kit (Illumina). Libraries were generated on the Sciclone G3 NGS (Perkin Elmer, Utah, USA) and the cDNA was amplified using 11 PCR cycles.</p><p id="P51">Libraries were pooled 75 samples per pool and sequenced using NovaSeq 6000 S4 reagents at 2x100bp to generate about 30 million reads per sample.</p></sec><sec id="S19"><title>RNA-seq data quality control and pre-processing</title><p id="P52">Quality control and alignment were performed using an in-house pipeline modified from previously published practices for RNA-seq analysis <sup><xref ref-type="bibr" rid="R39">39</xref>,<xref ref-type="bibr" rid="R40">40</xref></sup> in linux command line. Briefly, the quality of the sequencing fastq files was analyzed using FastQC (v0.11.5) and poor quality samples were excluded from further analysis. Sequence reads were adapter and quality trimmed using Trimmomatic (v0.36), followed by duplicated optical read removal using BBMap (v38.79) tool. STAR aligner (v2.5.2a) was used to align the reads to the human reference genome (GRCh38 build 99) downloaded from Ensembl, allowing for maximum 2 mismatches in each 25 bp segment and a maximum of 20 alignment hits per read <sup><xref ref-type="bibr" rid="R41">41</xref>,<xref ref-type="bibr" rid="R42">42</xref></sup>. The alignment results were sorted and indexed for downstream analyses as BAM format files. The aligned reads were further utilized to generate gene expression counts using FeatureCounts (v2.0.0) against the human reference annotation (GRCh38 build 99) <sup><xref ref-type="bibr" rid="R43">43</xref></sup>. Next, 60,067 genes in the expression matrix were first normalized by variance stabilizing transformation method built in DESeq2 package in R <sup><xref ref-type="bibr" rid="R44">44</xref></sup>. Subsequently, the batch effect was removed for 20,000 most variable genes using combat function in the SVA package with correcting for 2 RNA-seq batches <sup><xref ref-type="bibr" rid="R45">45</xref></sup>. The results of batch effect removal were visualized by principle component analysis. The first component was plotted against the second component. The variation explained by RNA-seq batches was removed after using combat (<xref ref-type="supplementary-material" rid="SD1">Figure S9</xref>). All later analysis and data visualization were done used batch corrected data.</p></sec><sec id="S20"><title>Validation of hub genes by Microfluidic multiplex RT-qPCR</title><p id="P53">Whole blood samples were collected, stored and RNA extraction was performed as described in the previous section. The expression of housekeeping genes (<italic>GAPDH</italic> and <italic>TMBIM6</italic>) and other hub genes were evaluated by microfluidic RT-qPCR using Biomark™ 48.48 Complete Bundle with Delta Gene™ Assays and BioMark™ HD system (Fluidigm Corporation, South San Francisco, CA, USA) following manufacturer’s instructions with some optimized modifications. Briefly, 2 μL of total RNA with concentration of 50 ng/μL was reverse transcribed to cDNA. The specific target amplification (STA) of cDNA was used for 14 cycles of preamplification, then the STA products were treated with Exonuclease I (New England Biolabs, Ipswich, MA, USA) before 20-fold dilution. SsoFast™ EvaGreen® Supermix with Low ROX (Bio-Rad Laboratories, Hercules, CA, USA) was used in RT-qPCR before applying to IFC Controllers MX and BioMark™ HD system (Fluidigm Corporation, South San Francisco, CA, USA). The cycle threshold (CT) values of target hub genes were normalized by subtracting for CT of <italic>GAPDH</italic> before analysis.</p></sec><sec id="S21"><title>Statistical analysis</title><p id="P54">The primary outcome examined in this study was TBM three-month mortality. In the descriptive analysis, we summarized and tested association of patient characteristics with three-month mortality using univariate Cox regression analysis. We presented the proportion for binary variables and median (1<sup>st</sup> and 3<sup>rd</sup> interquartile range) for continuous variables.</p><p id="P55">To explore transcriptional profiles associated with mortality in TBM, differential expression analysis was performed on the 20,000 normalized gene expression matrix to find differentially expressed genes (DEGs). We constructed the contradicted matrix with survival and death status adjusted for covariates including: age, HIV status, dexamethasone treatment (LAST-ACT trial investigators remained blind), and sequencing batch. Linear models were used to assess DEGs using limma R package. Empirical Bayes moderated-t p-values were computed for each genes and Benjamini-Hochberg were used for correcting multiple testing (FDR). We defined the DEGs with the parameters (fold change &gt; 1.5 and FDR &lt; 0.05). To visualize samples clustering in the 4 cohorts, an unsupervised principal component analysis was performed on 20,000 normalized genes, and the first principle component was plotted against the second principle component. The 95% confidence ellipse was drawn for each group using multivariate t-distribution ellipse. To compare enrichment activity of interested pathways between death vs survival, TBM vs PTB or healthy controls, enrichment scores of these pathways were calculated for single patient using single sample Gene Set Enrichment Analysis algorithm (ssGSEA). Pairwise Wilcoxon rank sum test was used for comparison between any two cohorts.</p><p id="P56">In the primary analysis, we initially conducted <italic>weighted gene co-expression network analysis</italic> (WGCNA) on the whole-blood transcriptomic profiling of the discovery cohort to identify clusters of genes (or ‘modules’) in the gene co-expression network among host transcriptomic genes. We then performed a <italic>network modules preservation analysis</italic> to assess the reproducibility of these modules and the network in the validation cohort. Subsequently, we conducted a <italic>module-trait association analysis</italic> to identify modules associated with the clinical traits of mortality and TBM severity. For the association analysis with mortality, we used a <italic>Cox regression model</italic> with the PC1 of the module as an independent variable. We adjusted the model for age, HIV status, and corticosteroid treatment (dexamethasone vs. placebo).</p><p id="P57">To analyze the association with TBM severity, we calculated the <italic>Spearman correlation</italic> between TBM severity (MRC grade) and the module’s PC1. We corrected for false discovery rate (FDR) for the dependent hypotheses by using the Benjamini-Yekutieli procedure. Target modules were defined as modules associated with mortality in both the discovery and validation cohorts at FDR &lt; 0.05. Hub genes within each targeted module were identified based on 3 criteria: being protein coding gene, module membership cut off 0.85 (MM) and high rank of gene significance rank (GS). MM defined as correlation between individual gene and the module’s PC1. GS defined as -log<sub>10</sub> p value association of gene with mortality using Cox regression model adjusted for age, HIV status and corticosteroid treatment. Genes were first filtered for protein coding function and MM above 0.85. Genes then was ranked based on its GS and top 20 hub genes were selected if number of genes in module above 500, otherwise top 10 genes were selected. Overlap hub genes between discovery and validation cohort were consider validated.</p><p id="P58">In the subsequent analysis, to determine the biological functions or processes potentially related to each module we conducted <italic>overrepresentation analysis</italic> (ORA) using ShinyGO v0.77 <sup><xref ref-type="bibr" rid="R19">19</xref></sup>. Genes were first filters for association with three-month mortality at p &lt; 0.05 and then were input into ShinyGO. We used both <italic>GO and KEGG databases</italic> for this analysis. We pre-specified significant pathways with overlap gene in pathway &gt; 5 and FDR &lt; 0.05.</p><p id="P59">Furthermore, to compare <italic>enrichment activity</italic> of resulting pathways between death vs survival, TBM vs PTB or healthy controls, enrichment scores of these pathways were calculated for single patient using ssGSEA algorithm <sup><xref ref-type="bibr" rid="R46">46</xref></sup>. Pairwise Wilcoxon rank rum test were applied for comparison between 2 cohorts. To compare or visualize the difference of pathway effect on mortality between HIV-negative and HIV-positive TBM, <italic>fold change enrichment</italic> of interested pathways were calculated using Quantitative Set Analysis for Gene Expression (QuSAGE) method <sup><xref ref-type="bibr" rid="R47">47</xref></sup>.</p><p id="P60">In the secondary analysis, we performed a <italic>consensus analysis</italic> to identify consensus patterns of co-expression networks between HIV-positive and HIV-negative conditions in our TBM cohort. We conducted similar association analyses for TBM severity and mortality as in the preceding WGCNA analysis for both the HIV-negative and HIV-positive cohorts. We visualized the results using a heatmap. We defined strongly associated modules in HIV-positive or HIV-negative cohort as HIV-positive-specific signals and HIV-negative-specific signals. Additionally, we functional enrichment ORA was performed for these consensus modules and the HIV-specific modules. Top 5 hub genes from HIV-specific modules were selected based on criteria described in the primary analysis, which included protein-coding genes and having high MM and high rank GS. GS in this analysis was calculated as -log<sub>10</sub> p value association of genes with mortality using Cox regression model adjusted for age and corticosteroid treatment.</p><p id="P61">We then performed variable selection using a <italic>multivariate elastic-net Cox regression model</italic> to select the important predictors for HIV-negative and HIV-positive TBM prognosis separately. Candidate predictors in HIV-negative TBM consisted of the combination of common hub genes, HIV-negative specific hub genes and clinical biomarkers: age, TBM severity and CSF lymphocyte count. Similarly, for HIV-positive TBM, candidate predictors consisted of common hub genes, HIV-positive specific hub genes and clinical biomarkers. We performed the analysis with 1,000 bootstrap sampling with replacement. The chosen variables were 1) among the top 75% of selected variables and 2) one representative hub gene per module. Subsequently, we developed a prediction model based on a <italic>logistic regression model</italic> incorporating only the chosen variables for all TBM cohort or stratified by HIV-negative and HIV-positive cohort. We also assessed predictive performance of chosen variables in each cohort by 1000 times bootstrapping sampling approach and reported the overall model performance (<italic>optimism-corrected Brier score</italic>), the discrimination (<italic>optimism-corrected AUC</italic>), and calibration (<italic>optimism-corrected calibration-slope</italic>) of the developed model <sup><xref ref-type="bibr" rid="R48">48</xref></sup>.</p><p id="P62">More details on performing ORA, SSGSEA, QuSAGE and WGCNA preservation and consensus analyses were provided in in the <xref ref-type="supplementary-material" rid="SD1">Supplementary method document</xref>.</p></sec></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary Materials</label><media xlink:href="EMS189452-supplement-Supplementary_Materials.pdf" mimetype="application" mime-subtype="pdf" id="d26aAdEbB" position="anchor"/></supplementary-material></sec></body><back><ack id="S22"><title>Acknowledgements</title><p>We would like to thank and the clinical staff who recruited patients into our study from Hospital for Tropical Diseases and Pham Ngoc Thach hospital, Ho Chi Minh city, Vietnam, and all participants.</p><sec id="S23"><title>Funding</title><p>This work was supported by Wellcome Trust Fellowship in Public Health and Tropical Medicine to NTTT (206724/Z/17/Z), Wellcome Trust Investigator Award to GT and Wellcome Trust to Vietnam Africa Asia Programme.</p></sec></ack><fn-group><fn fn-type="conflict" id="FN2"><p id="P63"><bold>Conflicts of Interest</bold></p><p id="P64">No conflicts of interest</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dodd</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>The global burden of tuberculous meningitis in adults: A modelling study</article-title><source>PLOS Glob Public Health</source><year>2021</year><volume>1</volume><elocation-id>e0000069</elocation-id><pub-id pub-id-type="pmcid">PMC10021871</pub-id><pub-id pub-id-type="pmid">36962116</pub-id><pub-id pub-id-type="doi">10.1371/journal.pgph.0000069</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stadelman</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Treatment Outcomes in Adult Tuberculous Meningitis: A Systematic Review and Meta-analysis</article-title><source>Open Forum Infect Dis</source><year>2020</year><volume>7</volume><elocation-id>ofaa257</elocation-id><pub-id pub-id-type="pmcid">PMC7423296</pub-id><pub-id pub-id-type="pmid">32818138</pub-id><pub-id pub-id-type="doi">10.1093/ofid/ofaa257</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkinson</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Tuberculous meningitis</article-title><source>Nat Rev Neurol</source><year>2017</year><volume>13</volume><fpage>581</fpage><lpage>598</lpage><pub-id pub-id-type="pmid">28884751</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huynh</surname><given-names>J</given-names></name><etal/></person-group><article-title>Tuberculous meningitis: progress and remaining questions</article-title><source>Lancet Neurol</source><year>2022</year><volume>21</volume><fpage>450</fpage><lpage>464</lpage><pub-id pub-id-type="pmid">35429482</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marais</surname><given-names>S</given-names></name><etal/></person-group><article-title>Inflammasome Activation Underlying Central Nervous System Deterioration in HIV-Associated Tuberculosis</article-title><source>J Infect Dis</source><year>2017</year><volume>215</volume><fpage>677</fpage><lpage>686</lpage><pub-id pub-id-type="pmcid">PMC5388298</pub-id><pub-id pub-id-type="pmid">27932622</pub-id><pub-id pub-id-type="doi">10.1093/infdis/jiw561</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rohlwink</surname><given-names>UK</given-names></name><etal/></person-group><article-title>Biomarkers of Cerebral Injury and Inflammation in Pediatric Tuberculous Meningitis</article-title><source>Clin Infect Dis</source><year>2017</year><volume>65</volume><fpage>1298</fpage><lpage>1307</lpage><pub-id pub-id-type="pmcid">PMC5815568</pub-id><pub-id pub-id-type="pmid">28605426</pub-id><pub-id pub-id-type="doi">10.1093/cid/cix540</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thuong</surname><given-names>NTT</given-names></name><etal/></person-group><article-title>Leukotriene A4 Hydrolase Genotype and HIV Infection Influence Intracerebral Inflammation and Survival From Tuberculous Meningitis</article-title><source>J Infect Dis</source><year>2017</year><volume>215</volume><fpage>1020</fpage><lpage>1028</lpage><pub-id pub-id-type="pmcid">PMC5426373</pub-id><pub-id pub-id-type="pmid">28419368</pub-id><pub-id pub-id-type="doi">10.1093/infdis/jix050</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thuong</surname><given-names>NTT</given-names></name><etal/></person-group><article-title>Pretreatment Cerebrospinal Fluid Bacterial Load Correlates With Inflammatory Response and Predicts Neurological Events During Tuberculous Meningitis Treatment</article-title><source>J Infect Dis</source><year>2019</year><volume>219</volume><fpage>986</fpage><lpage>995</lpage><pub-id pub-id-type="pmcid">PMC6386814</pub-id><pub-id pub-id-type="pmid">30299487</pub-id><pub-id pub-id-type="doi">10.1093/infdis/jiy588</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Laarhoven</surname><given-names>A</given-names></name><etal/></person-group><article-title>Clinical Parameters, Routine Inflammatory Markers, and LTA4H Genotype as Predictors of Mortality Among 608 Patients With Tuberculous Meningitis in Indonesia</article-title><source>J Infect Dis</source><year>2017</year><volume>215</volume><fpage>1029</fpage><lpage>1039</lpage><pub-id pub-id-type="pmid">28419315</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Laarhoven</surname><given-names>A</given-names></name><etal/></person-group><article-title>Immune cell characteristics and cytokine responses in adult HIV-negative tuberculous meningitis: an observational cohort study</article-title><source>Sci Rep</source><year>2019</year><volume>9</volume><fpage>884</fpage><pub-id pub-id-type="pmcid">PMC6351535</pub-id><pub-id pub-id-type="pmid">30696839</pub-id><pub-id pub-id-type="doi">10.1038/s41598-018-36696-3</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cresswell</surname><given-names>FV</given-names></name><etal/></person-group><article-title>Recent Developments in Tuberculous Meningitis Pathogenesis and Diagnostics</article-title><source>Wellcome Open Res</source><year>2019</year><volume>4</volume><fpage>164</fpage><pub-id pub-id-type="pmcid">PMC7739117</pub-id><pub-id pub-id-type="pmid">33364436</pub-id><pub-id pub-id-type="doi">10.12688/wellcomeopenres.15506.3</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rohlwink</surname><given-names>UK</given-names></name><etal/></person-group><article-title>Tuberculous meningitis in children is characterized by compartmentalized immune responses and neural excitotoxicity</article-title><source>Nat Commun</source><year>2019</year><volume>10</volume><elocation-id>3767</elocation-id><pub-id pub-id-type="pmcid">PMC6704154</pub-id><pub-id pub-id-type="pmid">31434901</pub-id><pub-id pub-id-type="doi">10.1038/s41467-019-11783-9</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ardiansyah</surname><given-names>E</given-names></name><etal/></person-group><article-title>Tryptophan metabolism determines outcome in tuberculous meningitis: a targeted metabolomic analysis</article-title><source>Elife</source><year>2023</year><volume>12</volume><pub-id pub-id-type="pmcid">PMC10181821</pub-id><pub-id pub-id-type="pmid">37158692</pub-id><pub-id pub-id-type="doi">10.7554/eLife.85307</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><collab>STREPTOMYCIN treatment of tuberculous meningitis</collab><source>Lancet</source><year>1948</year><volume>1</volume><fpage>582</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">18911226</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thao</surname><given-names>LTP</given-names></name><etal/></person-group><article-title>Prognostic Models for 9-Month Mortality in Tuberculous Meningitis</article-title><source>Clin Infect Dis</source><year>2018</year><volume>66</volume><fpage>523</fpage><lpage>532</lpage><pub-id pub-id-type="pmcid">PMC5850565</pub-id><pub-id pub-id-type="pmid">29029055</pub-id><pub-id pub-id-type="doi">10.1093/cid/cix849</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sweeney</surname><given-names>TE</given-names></name><name><surname>Braviak</surname><given-names>L</given-names></name><name><surname>Tato</surname><given-names>CM</given-names></name><name><surname>Khatri</surname><given-names>P</given-names></name></person-group><article-title>Genome-wide expression for diagnosis of pulmonary tuberculosis: a multicohort analysis</article-title><source>Lancet Respir Med</source><year>2016</year><volume>4</volume><fpage>213</fpage><lpage>24</lpage><pub-id pub-id-type="pmcid">PMC4838193</pub-id><pub-id pub-id-type="pmid">26907218</pub-id><pub-id pub-id-type="doi">10.1016/S2213-2600(16)00048-5</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penn-Nicholson</surname><given-names>A</given-names></name><etal/></person-group><article-title>RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response</article-title><source>Sci Rep</source><year>2020</year><volume>10</volume><elocation-id>8629</elocation-id><pub-id pub-id-type="pmcid">PMC7248089</pub-id><pub-id pub-id-type="pmid">32451443</pub-id><pub-id pub-id-type="doi">10.1038/s41598-020-65043-8</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marais</surname><given-names>S</given-names></name><etal/></person-group><article-title>Tuberculous meningitis: a uniform case definition for use in clinical research</article-title><source>Lancet Infect Dis</source><year>2010</year><volume>10</volume><fpage>803</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">20822958</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ge</surname><given-names>SX</given-names></name><name><surname>Jung</surname><given-names>D</given-names></name><name><surname>Yao</surname><given-names>R</given-names></name></person-group><article-title>ShinyGO: a graphical gene-set enrichment tool for animals and plants</article-title><source>Bioinformatics</source><year>2020</year><volume>36</volume><fpage>2628</fpage><lpage>2629</lpage><pub-id pub-id-type="pmcid">PMC7178415</pub-id><pub-id pub-id-type="pmid">31882993</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/btz931</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry</surname><given-names>MP</given-names></name><etal/></person-group><article-title>An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis</article-title><source>Nature</source><year>2010</year><volume>466</volume><fpage>973</fpage><lpage>7</lpage><pub-id pub-id-type="pmcid">PMC3492754</pub-id><pub-id pub-id-type="pmid">20725040</pub-id><pub-id pub-id-type="doi">10.1038/nature09247</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singhania</surname><given-names>A</given-names></name><etal/></person-group><article-title>A modular transcriptional signature identifies phenotypic heterogeneity of human tuberculosis infection</article-title><source>Nat Commun</source><year>2018</year><volume>9</volume><elocation-id>2308</elocation-id><pub-id pub-id-type="pmcid">PMC6008327</pub-id><pub-id pub-id-type="pmid">29921861</pub-id><pub-id pub-id-type="doi">10.1038/s41467-018-04579-w</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geng</surname><given-names>X</given-names></name><etal/></person-group><article-title>Whole transcriptome sequencing reveals neutrophils’ transcriptional landscape associated with active tuberculosis</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><elocation-id>954221</elocation-id><pub-id pub-id-type="pmcid">PMC9436479</pub-id><pub-id pub-id-type="pmid">36059536</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.954221</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castro-Alcaraz</surname><given-names>S</given-names></name><name><surname>Miskolci</surname><given-names>V</given-names></name><name><surname>Kalasapudi</surname><given-names>B</given-names></name><name><surname>Davidson</surname><given-names>D</given-names></name><name><surname>Vancurova</surname><given-names>I</given-names></name></person-group><article-title>NF-kappa B regulation in human neutrophils by nuclear I kappa B alpha: correlation to apoptosis</article-title><source>J Immunol</source><year>2002</year><volume>169</volume><fpage>3947</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">12244195</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabroe</surname><given-names>I</given-names></name><name><surname>Dower</surname><given-names>SK</given-names></name><name><surname>Whyte</surname><given-names>MK</given-names></name></person-group><article-title>The role of Toll-like receptors in the regulation of neutrophil migration, activation, and apoptosis</article-title><source>Clin Infect Dis</source><year>2005</year><volume>41 Suppl 7</volume><fpage>S421</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">16237641</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davoudi</surname><given-names>S</given-names></name><etal/></person-group><article-title>CD4+ cell counts in patients with different clinical manifestations of tuberculosis</article-title><source>Braz J Infect Dis</source><year>2008</year><volume>12</volume><fpage>483</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">19287835</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shridhar</surname><given-names>A</given-names></name><etal/></person-group><article-title>Prevalence of primary immunodeficiency syndromes in tuberculous meningitis: A case-control study</article-title><source>J Infect Public Health</source><year>2022</year><volume>15</volume><fpage>29</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">34883295</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>An</surname><given-names>HR</given-names></name><etal/></person-group><article-title>The relationship between absolute counts of lymphocyte subsets and clinical features in patients with pulmonary tuberculosis</article-title><source>Clin Respir J</source><year>2022</year><volume>16</volume><fpage>369</fpage><lpage>379</lpage><pub-id pub-id-type="pmcid">PMC9366570</pub-id><pub-id pub-id-type="pmid">35522050</pub-id><pub-id pub-id-type="doi">10.1111/crj.13490</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hemingway</surname><given-names>C</given-names></name><etal/></person-group><article-title>Childhood tuberculosis is associated with decreased abundance of T cell gene transcripts and impaired T cell function</article-title><source>PLoS One</source><year>2017</year><volume>12</volume><elocation-id>e0185973</elocation-id><pub-id pub-id-type="pmcid">PMC5687722</pub-id><pub-id pub-id-type="pmid">29140996</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0185973</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>LL</given-names></name><etal/></person-group><article-title>A Functional Role for Antibodies in Tuberculosis</article-title><source>Cell</source><year>2016</year><volume>167</volume><fpage>433</fpage><lpage>443</lpage><elocation-id>e14</elocation-id><pub-id pub-id-type="pmcid">PMC5526202</pub-id><pub-id pub-id-type="pmid">27667685</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2016.08.072</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manna</surname><given-names>La</given-names></name><etal/></person-group><article-title>Impact of Mycobacterium tuberculosis Infection on Human B Cell Compartment and Antibody Responses</article-title><source>Cells</source><year>2022</year><volume>11</volume><pub-id pub-id-type="pmcid">PMC9497247</pub-id><pub-id pub-id-type="pmid">36139482</pub-id><pub-id pub-id-type="doi">10.3390/cells11182906</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thwaites</surname><given-names>GE</given-names></name><etal/></person-group><article-title>Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults</article-title><source>N Engl J Med</source><year>2004</year><volume>351</volume><fpage>1741</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">15496623</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donovan</surname><given-names>J</given-names></name><etal/></person-group><article-title>Adjunctive Dexamethasone for Tuberculous Meningitis in HIV-Positive Adults</article-title><source>N Engl J Med</source><year>2023</year><volume>389</volume><fpage>1357</fpage><lpage>1367</lpage><pub-id pub-id-type="pmcid">PMC7615197</pub-id><pub-id pub-id-type="pmid">37819954</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa2216218</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>NP</given-names></name><name><surname>Banurekha</surname><given-names>VV</given-names></name><name><surname>Nair</surname><given-names>D</given-names></name><name><surname>Babu</surname><given-names>S</given-names></name></person-group><article-title>Circulating Angiogenic Factors as Biomarkers of Disease Severity and Bacterial Burden in Pulmonary Tuberculosis</article-title><source>PLoS One</source><year>2016</year><volume>11</volume><elocation-id>e0146318</elocation-id><pub-id pub-id-type="pmcid">PMC4699686</pub-id><pub-id pub-id-type="pmid">26727122</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0146318</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thao</surname><given-names>LTP</given-names></name><etal/></person-group><article-title>Dynamic Prediction of Death in Patients With Tuberculous Meningitis Using Time-updated Glasgow Coma Scale and Plasma Sodium Measurements</article-title><source>Clin Infect Dis</source><year>2020</year><volume>70</volume><fpage>827</fpage><lpage>834</lpage><pub-id pub-id-type="pmid">30944929</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>B</given-names></name><etal/></person-group><article-title>Prognostic factors of adult tuberculous meningitis in intensive care unit: a single-center retrospective study in East China</article-title><source>BMC Neurol</source><year>2021</year><volume>21</volume><fpage>308</fpage><pub-id pub-id-type="pmcid">PMC8353730</pub-id><pub-id pub-id-type="pmid">34376174</pub-id><pub-id pub-id-type="doi">10.1186/s12883-021-02340-3</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharawat</surname><given-names>IK</given-names></name><etal/></person-group><article-title>Development and Validation of a Prognostic Model and Bedside Score for the Neurological Outcome in Children with Tuberculous Meningitis</article-title><source>Am J Trop Med Hyg</source><year>2022</year><volume>107</volume><fpage>1288</fpage><lpage>1294</lpage><pub-id pub-id-type="pmcid">PMC9768285</pub-id><pub-id pub-id-type="pmid">36216321</pub-id><pub-id pub-id-type="doi">10.4269/ajtmh.22-0253</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donovan</surname><given-names>J</given-names></name><etal/></person-group><article-title>Adjunctive dexamethasone for the treatment of HIV-uninfected adults with tuberculous meningitis stratified by Leukotriene A4 hydrolase genotype (LAST ACT): Study protocol for a randomised double blind placebo controlled non-inferiority trial</article-title><source>Wellcome Open Res</source><year>2018</year><volume>3</volume><fpage>32</fpage><pub-id pub-id-type="pmcid">PMC6182672</pub-id><pub-id pub-id-type="pmid">30363837</pub-id><pub-id pub-id-type="doi">10.12688/wellcomeopenres.14007.1</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donovan</surname><given-names>J</given-names></name><etal/></person-group><article-title>Adjunctive dexamethasone for the treatment of HIV-infected adults with tuberculous meningitis (ACT HIV): Study protocol for a randomised controlled trial</article-title><source>Wellcome Open Res</source><year>2018</year><volume>3</volume><fpage>31</fpage><pub-id pub-id-type="pmcid">PMC6143919</pub-id><pub-id pub-id-type="pmid">30320225</pub-id><pub-id pub-id-type="doi">10.12688/wellcomeopenres.14006.1</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yalamanchili</surname><given-names>HK</given-names></name><name><surname>Wan</surname><given-names>YW</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name></person-group><article-title>Data Analysis Pipeline for RNA-seq Experiments: From Differential Expression to Cryptic Splicing</article-title><source>Curr Protoc Bioinformatics</source><year>2017</year><volume>59</volume><fpage>11 15 1</fpage><lpage>11 15 21</lpage><pub-id pub-id-type="pmcid">PMC6373869</pub-id><pub-id pub-id-type="pmid">28902396</pub-id><pub-id pub-id-type="doi">10.1002/cpbi.33</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conesa</surname><given-names>A</given-names></name><etal/></person-group><article-title>A survey of best practices for RNA-seq data analysis</article-title><source>Genome Biol</source><year>2016</year><volume>17</volume><fpage>13</fpage><pub-id pub-id-type="pmcid">PMC4728800</pub-id><pub-id pub-id-type="pmid">26813401</pub-id><pub-id pub-id-type="doi">10.1186/s13059-016-0881-8</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname><given-names>A</given-names></name><etal/></person-group><article-title>STAR: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><year>2013</year><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="pmcid">PMC3530905</pub-id><pub-id pub-id-type="pmid">23104886</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolger</surname><given-names>AM</given-names></name><name><surname>Lohse</surname><given-names>M</given-names></name><name><surname>Usadel</surname><given-names>B</given-names></name></person-group><article-title>Trimmomatic: a flexible trimmer for Illumina sequence data</article-title><source>Bioinformatics</source><year>2014</year><volume>30</volume><fpage>2114</fpage><lpage>20</lpage><pub-id pub-id-type="pmcid">PMC4103590</pub-id><pub-id pub-id-type="pmid">24695404</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/btu170</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name></person-group><article-title>featureCounts: an efficient general purpose program for assigning sequence reads to genomic features</article-title><source>Bioinformatics</source><year>2014</year><volume>30</volume><fpage>923</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">24227677</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biol</source><year>2014</year><volume>15</volume><fpage>550</fpage><pub-id pub-id-type="pmcid">PMC4302049</pub-id><pub-id pub-id-type="pmid">25516281</pub-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leek</surname><given-names>JT</given-names></name><name><surname>Johnson</surname><given-names>WE</given-names></name><name><surname>Parker</surname><given-names>HS</given-names></name><name><surname>Jaffe</surname><given-names>AE</given-names></name><name><surname>Storey</surname><given-names>JD</given-names></name></person-group><article-title>The sva package for removing batch effects and other unwanted variation in high-throughput experiments</article-title><source>Bioinformatics</source><year>2012</year><volume>28</volume><fpage>882</fpage><lpage>3</lpage><pub-id pub-id-type="pmcid">PMC3307112</pub-id><pub-id pub-id-type="pmid">22257669</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/bts034</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbie</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1</article-title><source>Nature</source><year>2009</year><volume>462</volume><fpage>108</fpage><lpage>12</lpage><pub-id pub-id-type="pmcid">PMC2783335</pub-id><pub-id pub-id-type="pmid">19847166</pub-id><pub-id pub-id-type="doi">10.1038/nature08460</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yaari</surname><given-names>G</given-names></name><name><surname>Bolen</surname><given-names>CR</given-names></name><name><surname>Thakar</surname><given-names>J</given-names></name><name><surname>Kleinstein</surname><given-names>SH</given-names></name></person-group><article-title>Quantitative set analysis for gene expression: a method to quantify gene set differential expression including gene-gene correlations</article-title><source>Nucleic Acids Res</source><year>2013</year><volume>41</volume><elocation-id>e170</elocation-id><pub-id pub-id-type="pmcid">PMC3794608</pub-id><pub-id pub-id-type="pmid">23921631</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkt660</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steyerberg</surname><given-names>EW</given-names></name><etal/></person-group><article-title>Internal validation of predictive models: efficiency of some procedures for logistic regression analysis</article-title><source>J Clin Epidemiol</source><year>2001</year><volume>54</volume><fpage>774</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">11470385</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><title>Objectives and cohorts flow</title><p>TBM: TB meningitis, HIV: human immunodeficiency virus, PTB: pulmonary TB, HC; healthy controls</p></caption><graphic xlink:href="EMS189452-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>Blood transcriptomic profiles of four cohorts: healthy controls (n=30), PTB (n=295), HIV-negative TBM (n=207) and HIV-positive TBM (n=74)</title><p>(A). Principle component analysis (PCA) of whole transcriptomic profile of HC, PTB PTB and TBM with and without HIV. Each symbol represents one individual with color coding different cohorts. The x-axis represents principle component (PC) 1, while y-axis represents PC2. <bold>(B-G)</bold> Enrichment scores of known innate immunity pathways associated with TBM pathogenesis. Gene list of these pathway were depicted in additional file 1, <xref ref-type="supplementary-material" rid="SD1">table S5</xref>. Pathway enrichment scores were calculated using single sample GSEA algorithm (ssGSEA) (Barbie DA, et al 2009). Each dot represents one participant. The box presents median, 25<sup>th</sup> to 75<sup>th</sup> percentile and the whiskers present the minimum to the maximum points in the data.</p></caption><graphic xlink:href="EMS189452-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>Blood transcriptomic profiles of three-month mortality at baseline in all TBM and TBM stratified by HIV status</title><p>Volcano plot showed differential expression (DE) genes by fold change (FC) between death and survival in all TBM <bold>(A)</bold>, HIV-negative <bold>(B)</bold> and HIV-positive TBM <bold>(C)</bold>. Each dot represents one gene. The x-axis represents log<sub>2</sub> FC. The y-axis showed –log<sub>10</sub> FDR of genes. DE genes were colored with red indicating up-regulated, blue indicating down-regulated genes which having fold discovery rate (FDR) &lt;0.05 and absolute FC &gt; 1.5.</p></caption><graphic xlink:href="EMS189452-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title>Blood transcriptional modules associated with mortality in TBM</title><p><bold>(A)</bold> Associations between WGCNA modules with two clinical phenotypes TBM disease severity (MRC grade) and three-month mortality in discovery and validation cohorts, and their associated biological processes. The heatmap showed the association between principle component 1 (PC1) of each module and the phenotypes, particularly Spearman correlation r for MRC grade and hazard ratio per increase 1/10 unit of PC1 (HR) for mortality. The HRs were estimated using a Cox regression model adjusted for age, HIV status and dexamethasone treatment. False discovery rate (FDR) corrected based on Benjamini &amp; Yekutieli procedure, with significant level denoted as * &lt; .05, ** &lt; .01 and *** &lt;.001. Gradient colors were used to fill the cell with green indicating negative r or HR &lt; 1, red color indicating positive r or HR &gt; 1. The order of modules was based on hierarchical clustering using Pearson correlation distance for module eigengene. On the left, biological processes, corresponding to modules, were identified using Gene Ontology and KEGG database. <bold>(B)</bold> Validation of the association between WGCNA modules and mortality in discovery and validation cohorts. X-axis represents –log<sub>10</sub> FDR in discovery cohort and Y-axis represents –log<sub>10</sub> FDR in validation cohort. Red dash lines indicate FDR = 0.05 as the threshold for statistically significant in both cohorts. Five modules (blue, brown, red, black and cyan) with FDR &lt; 0.05 were validated.</p></caption><graphic xlink:href="EMS189452-f004"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><title>Biological processes, pathways and hub genes of validated modules associated with mortality</title><p><bold>(A-D)</bold> showed biological processes and pathways identified in four mortality associated modules: blue, brown, red and black module, by over representation analysis (ORA). Bar plots show the top representative GO biological processes or KEGG pathways. The bars indicates biological processes or pathways having ORA FDR &lt; 0.05 and size corresponding to fold enrichment calculated as the ratio of gene number of pathway in the input list divided by the ratio of gene number of the pathway in reference. <bold>(E-H)</bold> showed gene co-expression networks and hub genes of blue, brown, red and black module, respectively. Each node represents one gene. Each edge represents the link between two genes. Hub genes were shown by bigger nodes and bold text. The gradient color of node corresponds to its HR to mortality, with red indicating HR &gt; 1, and blue HR &lt; 1.</p></caption><graphic xlink:href="EMS189452-f005"/></fig><fig id="F6" position="float"><label>Figure 6</label><caption><title>Gene expression of representative hub genes in healthy controls (n=30), PTB (n=295), HIV-negative TBM (n=207) and HIV-positive TBM (n=74)</title><p>Each dot represents gene expression from one participant. <bold>(A, B)</bold> expression of FCAR and MCEMP1 hub genes from the blue module. <bold>(C, D)</bold> expression of NELL2 and TRABD2A hub genes from the brown modules. <bold>(E, F)</bold> expression of PLCG1 and NLRC3 hub genes from the red module. <bold>(G, H)</bold> expression of CD247 and MATK hub genes from the black module. The box presents median, 25<sup>th</sup> to 75<sup>th</sup> percentile and the whiskers present the minimum to the maximum points in the data. Comparisons were made between dead (red) with survival (blue) or between HIV-negative and HIV-positive TBM by Wilcoxon rank sum test with p-values displayed as significance level above the boxes and the horizontal bars (* &lt; .05, ** &lt; .01, *** &lt;.001).</p></caption><graphic xlink:href="EMS189452-f006"/></fig><fig id="F7" position="float"><label>Figure 7</label><caption><title>Relationship between known pathways associated with TBM pathogenesis and mortality</title><p>Enrichment scores of known immune pathways associated with TBM pathogenesis. Gene list of these pathway were depicted in additional file 1, <xref ref-type="supplementary-material" rid="SD1">table S5</xref>. Pathway enrichment scores were calculated using single sample GSEA algorithm (ssGSEA) (Barbie DA, et al 2009). Each dot represents one participant. The box presents median, 25<sup>th</sup> to 75<sup>th</sup> percentile and the whiskers present the minimum to the maximum points in the data. The comparisons were made between survival and death using Wilcoxon rank sum test. Only significant results are presented with * &lt; .05, ** &lt; .01, *** &lt;.001.</p></caption><graphic xlink:href="EMS189452-f007"/></fig><fig id="F8" position="float"><label>Figure 8</label><caption><title>Consensus transcriptional modules associated with TBM mortality stratified by HIV-infection</title><p><bold>(A)</bold> Associations between 16 consensus WGCNA modules with two clinical phenotypes TBM severity (MRC grade) and mortality in HIV-negative (n=207) and HIV-positive (n=74) TBM participants, and their associated BP Gene ontology or KEEG database. The heatmap showed the association between modules and the phenotypes, with Spearman correlation r for MRC grade and hazard ratio per increase 1 unit of PC1 of module (HR) for mortality in HIV-positive and HIV-negative cohorts. The consensus sub-panel presented associations of the consensus modules and clinical phenotypes with same trend detected in both HIV cohorts, otherwise were annotated with missing (NA) values. False discovery rate (FDR) corrected using Benjamini &amp; Yekutieli procedure, with significant level denoted as * &lt; .05, ** &lt; .01 and *** &lt;.001. Gradient colors were used to fill the cell with green indicating negative r or HR &lt; 1, red color indicating positive r or HR &gt; 1. The order of modules was based on hierarchical clustering using Pearson correlation distance for module eigengene. It is noted that these consensus modules were not identical to the identified modules in the primary analysis in <xref ref-type="fig" rid="F1">Figure 1</xref>. <bold>(B-C)</bold> Functional enrichment analysis of HIV-positive pathway (blue module) and HIV-negative pathway (yellow module), respectively. <bold>(D-E)</bold> Gene co-expression network of blue and yellow modules. Each node represents one gene. Each edge represents the link between two genes. Hub genes were shown by bigger nodes with bold text. The gradient color of node corresponds to its HR to mortality, with red indicating HR&gt;1, and blue HR&lt;1.</p></caption><graphic xlink:href="EMS189452-f008"/></fig><fig id="F9" position="float"><label>Figure 9</label><caption><title>Enrichment score of immunity pathways in healthy controls (n=30), PTB (n=295), HIV-negative TBM (n=207) and HIV-positive TBM (n=74)</title><p>Pathway enrichment scores were calculated using single sample GSEA algorithm (ssGSEA) (Barbie DA, et al 2009). Each dot represents one participant. <bold>(A-C)</bold> showed box-plots depicting enrichment scores of the innate immunity pathways from the blue module. <bold>(E-H)</bold> enrichment scores of the adaptive immunity pathways from the red and brown modules. <bold>(D)</bold> normalized expression of TNF. Gene list of these pathway were depicted in additional file 1, <xref ref-type="supplementary-material" rid="SD1">table S5</xref>. The box presents median, 25<sup>th</sup> to 75<sup>th</sup> percentile and the whiskers present the minimum to the maximum points in the data. Comparisons were made between dead (red) with survival (blue) or between HIV-negative and HIV-positive TBM by Wilcoxon rank sum test with p-values displayed as significance level above the boxes and the horizontal bars, respectively (* &lt; .05, ** &lt; .01, *** &lt;.001).</p></caption><graphic xlink:href="EMS189452-f009"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Baseline characteristics of TBM, PTB, and healthy controls</title></caption><table frame="box" rules="groups"><thead><tr><th rowspan="3" valign="middle" align="center" style="border-top:solid thin; border-left:solid thin">Characteristics</th><th colspan="8" valign="top" align="center" style="border-top: solid thin; border-left: solid thin">RNA-seq cohorts</th><th colspan="2" valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin">qPCR validation cohort</th></tr><tr><th colspan="2" valign="top" align="center" style="border-top: solid thin; border-left: solid thin">HIV-negative TBM n=207</th><th colspan="2" valign="top" align="center" style="border-top: solid thin; border-left: solid thin">HIV-positive TBM n=74</th><th colspan="2" valign="top" align="center" style="border-top: solid thin; border-left: solid thin">PTB n=295</th><th colspan="2" valign="top" align="center" style="border-top: solid thin; border-left: solid thin">Healthy controls n=30</th><th colspan="2" valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin">HIV-negative TBM n=132</th></tr><tr><th valign="top" align="center" style="border-top: solid thin; border-left: solid thin">n</th><th valign="top" align="center" style="border-top: solid thin; border-left: solid thin">Summary</th><th valign="top" align="center" style="border-top: solid thin; border-left: solid thin">n</th><th valign="top" align="center" style="border-top: solid thin; border-left: solid thin">Summary</th><th valign="top" align="center" style="border-top: solid thin; border-left: solid thin">n</th><th valign="top" align="center" style="border-top: solid thin; border-left: solid thin">Summary</th><th valign="top" align="center" style="border-top: solid thin; border-left: solid thin">n</th><th valign="top" align="center" style="border-top: solid thin; border-left: solid thin">Summary</th><th valign="top" align="center" style="border-top: solid thin; border-left: solid thin">n</th><th valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin">Summary</th></tr></thead><tbody><tr><td valign="top" align="left" style="border-top: solid thin; border-left: solid thin"><bold>Age (years)</bold></td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">207</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">46 (34, 58)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">74</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">34 (29, 40)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">295</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">44 (31, 52)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">30</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">33 (29, 37)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">132</td><td valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin">48 (35, 60)</td></tr><tr><td valign="top" align="left" style="border-top: solid thin; border-left: solid thin"><bold>Male sex</bold></td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">207</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">127 (61)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">74</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">56 (76)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">295</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">228 (77)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">30</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">11 (37)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">132</td><td valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin">84 (65)</td></tr><tr><td valign="top" align="left" style="border-top: solid thin; border-left: solid thin"><bold>BMI (kg/m2)</bold></td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">205</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">20.0 (18.2, 22.3)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">72</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">19.3 (17.2, 20.4)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">295</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">19.4 (17.7, 21.6)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">132</td><td valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin">20.0 (18.2, 22.3)</td></tr><tr><td valign="top" align="left" style="border-top: solid thin; border-left: solid thin"><bold>Symptom duration (days)</bold></td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">207</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">14 (11, 20)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">73</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">16 (10, 30)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">294</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">20 (10, 30)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">132</td><td valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin">16 (13, 24)</td></tr><tr><td valign="top" align="left" style="border-top: solid thin; border-left: solid thin"><bold>History of TB treatment</bold></td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">204</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">5 (2.5)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">74</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">15 (20)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">295</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">100 (34)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">130</td><td valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin">12 (9.2)</td></tr><tr><td valign="top" align="left" style="border-top: solid thin; border-left: solid thin"><bold>Glasgow coma score</bold></td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">207</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">14 (12, 15)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">72</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">14 (13, 15)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">132</td><td valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin">14 (13, 15)</td></tr><tr><td valign="top" align="left" style="border-top: solid thin; border-left: solid thin"><bold>Cavity chest X-ray</bold></td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">270</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">129 (48)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin"/></tr><tr><td valign="top" align="left" style="border-top: solid thin; border-left: solid thin"><bold>TB microbiological tests</bold></td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin"/></tr><tr><td valign="top" align="left" style="border-top: solid thin; border-left: solid thin">  MGIT culture positive</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">199</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">50 (25)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">69</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">41 (59)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">295</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">279 (95)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin"/></tr><tr><td valign="top" align="left" style="border-top: solid thin; border-left: solid thin">  Xpert/Ultra positive</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">198</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">42 (21)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">70</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">39 (56)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">295</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">287 (97)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin"/></tr><tr><td valign="top" align="left" style="border-top: solid thin; border-left: solid thin">  Microscopy positive</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">205</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">48 (23)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">67</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">35 (52)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">203</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">169 (83)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">105</td><td valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin">18 (17)</td></tr><tr><td valign="top" align="left" style="border-top: solid thin; border-left: solid thin"><bold>Blood (106 cells/ml)</bold></td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin"/></tr><tr><td valign="top" align="left" style="border-top: solid thin; border-left: solid thin">  Leucocyte count</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">204</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">9.4 (7.0, 11.9)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">74</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">6.4 (5.0, 9.2)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">242</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">9.2 (7.4, 11.4)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">26</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">6.4 (5.6, 7.2)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">129</td><td valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin">10.0 (7.7, 12.4)</td></tr><tr><td valign="top" align="left" style="border-top: solid thin; border-left: solid thin">  Neutrophil count</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">204</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">7.1 (4.8, 9.1)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">74</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">5.0 (3.3, 6.9)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">241</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">6.1 (4.7, 8.2)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">26</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">3.4 (3.1, 4.1)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">129</td><td valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin">7.8 (6.9, 8.5)</td></tr><tr><td valign="top" align="left" style="border-top: solid thin; border-bottom: solid thin; border-left: solid thin">  Lymphocytes count</td><td valign="top" align="center" style="border-top: solid thin; border-bottom: solid thin; border-left: solid thin">204</td><td valign="top" align="center" style="border-top: solid thin; border-bottom: solid thin; border-left: solid thin">1.2 (0.9, 2.0)</td><td valign="top" align="center" style="border-top: solid thin; border-bottom: solid thin; border-left: solid thin">74</td><td valign="top" align="center" style="border-top: solid thin; border-bottom: solid thin; border-left: solid thin">0.7 (0.4, 1.2)</td><td valign="top" align="center" style="border-top: solid thin; border-bottom: solid thin; border-left: solid thin">242</td><td valign="top" align="center" style="border-top: solid thin; border-bottom: solid thin; border-left: solid thin">1.9 (1.4, 2.3)</td><td valign="top" align="center" style="border-top: solid thin; border-bottom: solid thin; border-left: solid thin">26</td><td valign="top" align="center" style="border-top: solid thin; border-bottom: solid thin; border-left: solid thin">2.2 (1.9, 2.6)</td><td valign="top" align="center" style="border-top: solid thin; border-bottom: solid thin; border-left: solid thin">129</td><td valign="top" align="center" style="border: solid thin">1.2 (0.7, 1.8)</td></tr><tr><td valign="top" align="left" style="border-left: solid thin; border-bottom: solid thin"><bold>CSF (103 cells/ml)</bold></td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-right: solid thin; border-bottom: solid thin; border-left: solid thin"/></tr><tr><td valign="top" align="left" style="border-left: solid thin; border-bottom: solid thin">  Leucocyte count</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">207</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">142 (19,323)</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">73</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">124 (10, 453)</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">106</td><td valign="top" align="center" style="border-right: solid thin; border-bottom: solid thin; border-left: solid thin">122 (38, 328)</td></tr><tr><td valign="top" align="left" style="border-left: solid thin; border-bottom: solid thin">  Neutrophil count</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">207</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">0 (0, 39)</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">73</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">17 (0, 144)</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">60</td><td valign="top" align="center" style="border-right: solid thin; border-bottom: solid thin; border-left: solid thin">20 (3, 73)</td></tr><tr><td valign="top" align="left" style="border-left: solid thin; border-bottom: solid thin">  Lymphocyte count</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">207</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">106 (18, 223)</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">73</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">58 (10, 216)</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">106</td><td valign="top" align="center" style="border-right: solid thin; border-bottom: solid thin; border-left: solid thin">95 (79, 100)</td></tr><tr><td valign="top" align="left" style="border-left: solid thin; border-bottom: solid thin"><bold>CD4 cell count (cells/ml)</bold></td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">73</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">67 (19, 124)</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-right: solid thin; border-bottom: solid thin; border-left: solid thin"/></tr><tr><td valign="top" align="left" style="border-left: solid thin; border-bottom: solid thin"><bold>Antiretroviral therapy</bold></td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">70</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">28 (39%)</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-right: solid thin; border-bottom: solid thin; border-left: solid thin"/></tr><tr><td valign="top" align="left" style="border-left: solid thin; border-bottom: solid thin"><bold>HIV load (103 cells/ml)</bold></td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">70</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">77.3 (8.28, 672)</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"/><td valign="top" align="center" style="border-right: solid thin; border-bottom: solid thin; border-left: solid thin"/></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p id="P65">Values were displayed as median (1<sup>st</sup> and 3<sup>rd</sup> interquartile) for continuous variables and frequency (%) for categorical variables.</p></fn><fn id="TFN2"><p id="P66">TBM = tuberculous meningitis, PTB= pulmonary tuberculosis, CSF= cerebrospinal fluid</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Association between baseline clinical characteristics with TBM mortality in RNA-seq cohorts</title></caption><table frame="box" rules="groups"><thead><tr><th rowspan="2" valign="middle" align="left" style="border-top:solid thin; border-left:solid thin">Characteristics</th><th colspan="6" valign="top" align="center" style="border-top: solid thin; border-left: solid thin">All TBM</th><th colspan="2" valign="top" align="center" style="border-top: solid thin; border-left: solid thin">Discovery cohort</th><th colspan="2" valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin">Validation cohort</th></tr><tr><th valign="top" align="center" style="border-top:solid thin; border-left:solid thin">n</th><th valign="top" align="center" style="border-top: solid thin; border-left: solid thin">Survival n=220</th><th valign="top" align="center" style="border-top: solid thin; border-left: solid thin">Death n=61</th><th valign="top" align="center" style="border-top:solid thin; border-left:solid thin">HR*</th><th valign="top" align="center" style="border-top:solid thin; border-left:solid thin">95% CI</th><th valign="top" align="center" style="border-top:solid thin; border-left:solid thin">p value<sup><xref ref-type="table-fn" rid="TFN4">*</xref></sup></th><th valign="top" align="center" style="border-top: solid thin; border-left: solid thin">Survival n=111</th><th valign="top" align="center" style="border-top: solid thin; border-left: solid thin">Death n=31</th><th valign="top" align="center" style="border-top: solid thin; border-left: solid thin">Survival n=109</th><th valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin">Death n=30</th></tr></thead><tbody><tr><td valign="top" align="left" style="border-top: solid thin; border-left: solid thin"><bold>Male sex</bold></td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">281</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">144 (65)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">39 (64)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">1.01</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">0.99, 1.02</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">0.3</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">70 (63)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">19 (61)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">74 (68)</td><td valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin">20 (67)</td></tr><tr><td valign="top" align="left" style="border-top: solid thin; border-left: solid thin"><bold>Age (years)</bold></td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">281</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">41 (32, 53)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">39 (30, 60)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">0.92</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">0.55, 1.56</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">0.8</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">41 (32, 53)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">47 (33, 64)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">41 (32, 53)</td><td valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin">34 (29, 58)</td></tr><tr><td valign="top" align="left" style="border-top: solid thin; border-left: solid thin"><bold>HIV infection</bold></td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">281</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">47 (21)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">27 (44)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">2.34</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">1.41, 3.89</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"><bold>&lt; 0.001</bold></td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">24 (22)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">14 (45)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">23 (21)</td><td valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin">13 (43)</td></tr><tr><td valign="top" align="left" style="border-top: solid thin; border-left: solid thin"><xref ref-type="table-fn" rid="TFN5">**</xref><bold>Diagnostic category</bold></td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">280</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin"/></tr><tr><td valign="top" align="left" style="border-top: solid thin; border-left: solid thin">  definite TBM</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">101 (46)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">32 (52)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">55 (50)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">17 (55)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">46 (42)</td><td valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin">15 (50)</td></tr><tr><td valign="top" align="left" style="border-top: solid thin; border-left: solid thin">  possible TBM</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">43 (20)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">6 (9.8)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">1.01</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">0.59, 1.72</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">0.9</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">20 (18)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">2 (6.5)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">23 (21)</td><td valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin">4 (13)</td></tr><tr><td valign="top" align="left" style="border-top: solid thin; border-left: solid thin">  probable TBM</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">75 (34)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">23 (38)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">0.50</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">0.21, 1.19</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">0.12</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">35 (32)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">12 (39)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">40 (37)</td><td valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin">11 (37)</td></tr><tr><td valign="top" align="left" style="border-top: solid thin; border-left: solid thin"><xref ref-type="table-fn" rid="TFN6">***</xref><bold>MRC grade</bold></td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">281</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin"/></tr><tr><td valign="top" align="left" style="border-top: solid thin; border-left: solid thin">  grade 1</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">114 (52)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">7 (11)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">58 (52)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">3 (9.7)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">56 (51)</td><td valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin">4 (13)</td></tr><tr><td valign="top" align="left" style="border-top: solid thin; border-left: solid thin">  grade 2</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">100 (45)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">35 (57)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">4.96</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">2.20, 11.2</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"><bold>&lt; 0.001</bold></td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">51 (46)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">18 (58)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">49 (45)</td><td valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin">17 (57)</td></tr><tr><td valign="top" align="left" style="border-top: solid thin; border-left: solid thin">  grade 3</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">6 (2.7)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">19 (31)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">26.4</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">11.0, 63.2</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"><bold>&lt; 0.001</bold></td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">2 (1.8)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">10 (32)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">4 (3.7)</td><td valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin">9 (30)</td></tr><tr><td valign="top" align="left" style="border-top: solid thin; border-left: solid thin"><bold>Blood (10<sup>6</sup> cells/ml)</bold></td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin"/></tr><tr><td valign="top" align="left" style="border-top: solid thin; border-left: solid thin">  Leukocyte count</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">278</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">8.1 (6.2, 10.7)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">10.1 (6.7, 12.2)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">4.49</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">1.13, 17.9</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"><bold>0.033</bold></td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">7.8 (6.2, 10.6)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">8.6 (6.4, 12.0)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">8.4 (6.4, 10.7)</td><td valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin">10.8 (7.6, 12.4)</td></tr><tr><td valign="top" align="left" style="border-top: solid thin; border-left: solid thin">  Neutrophil count</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">278</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">6.0 (4.0, 8.1)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">8.0 (5.0, 10.3)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">7.44</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">2.34, 23.6</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"><bold>&lt; 0.001</bold></td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">5.9 (4.0, 8.1)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">6.7 (4.9, 9.6)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">6.4 (4.0, 8.2)</td><td valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin">9.0 (5.8, 10.3)</td></tr><tr><td valign="top" align="left" style="border-top: solid thin; border-left: solid thin">  Lymphocyte count</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">278</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">1.2 (0.8, 1.9)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">0.9 (0.5, 1.2)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">0.31</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">0.15, 0.66</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin"><bold>0.002</bold></td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">1.2 (0.7, 2.0)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">1.0 (0.6, 1.3)</td><td valign="top" align="center" style="border-top: solid thin; border-left: solid thin">1.3 (0.9, 1.9)</td><td valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin">0.8 (0.5, 1.2)</td></tr><tr><td valign="top" align="left" style="border-top: solid thin; border-bottom: solid thin; border-left: solid thin"><bold>CSF (10<sup>3</sup> cells/ml)</bold></td><td valign="top" align="center" style="border-top: solid thin; border-bottom: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-bottom: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-bottom: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-bottom: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-bottom: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-bottom: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-bottom: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-bottom: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border-top: solid thin; border-bottom: solid thin; border-left: solid thin"/><td valign="top" align="center" style="border: solid thin"/></tr><tr><td valign="top" align="left" style="border-left: solid thin; border-bottom: solid thin">  Leukocyte count</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">280</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">129 (19, 340)</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">148 (15, 360)</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">0.98</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">0.72, 1.33</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">0.9</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">130 (17, 348)</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">148 (15, 444)</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">124 (27, 335)</td><td valign="top" align="center" style="border-right: solid thin; border-bottom: solid thin; border-left: solid thin">146 (25, 283)</td></tr><tr><td valign="top" align="left" style="border-left: solid thin; border-bottom: solid thin">  Neutrophil count</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">117</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">0 (0, 49)</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">0 (0, 97)</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">1.97</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">1.03, 3.76</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin"><bold>0.040</bold></td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">3 (0, 53)</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">0 (0, 106)</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">0 (0, 36)</td><td valign="top" align="center" style="border-right: solid thin; border-bottom: solid thin; border-left: solid thin">25 (0, 94)</td></tr><tr><td valign="top" align="left" style="border-left: solid thin; border-bottom: solid thin">  Lymphocyte count</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">280</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">101 (18, 229)</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">91 (14, 176)</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">0.83</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">0.60, 1.16</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">0.3</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">104 (16, 208)</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">123 (10, 214)</td><td valign="top" align="center" style="border-left: solid thin; border-bottom: solid thin">97 (21, 248)</td><td valign="top" align="center" style="border-right: solid thin; border-bottom: solid thin; border-left: solid thin">86 (14, 147)</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p id="P67">Values were displayed as median (1<sup>st</sup> and 3<sup>rd</sup> interquartile) for continuous variables and frequency (%) for categorical variables.</p></fn><fn id="TFN4"><label>*</label><p id="P68">Association of the corresponding variables with three-month mortality using a Cox regression model. Hazard ratio (HR) and p-value from the Cox regression model were presented in the table.</p></fn><fn id="TFN5"><label>**</label><p id="P69">Diagnostic categories were assigned according to the consensus case definition <sup><xref ref-type="bibr" rid="R18">18</xref></sup>. Definite TBM refers to cases that are microbiological confirmed TB by microscopy, culture and Xpert using CSF samples.</p></fn><fn id="TFN6"><label>***</label><p id="P70">MRC grade denotes modified British Medical Research Council criteria <sup><xref ref-type="bibr" rid="R14">14</xref></sup>.</p></fn><fn id="TFN7"><p id="P71">TBM = tuberculous meningitis, CSF= cerebrospinal fluid</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Validation of hub genes in PCR validation cohort</title></caption><table frame="box" rules="groups"><thead><tr><th rowspan="2" valign="top" align="center" style="border-top: solid thin; border-left: solid thin">No.</th><th rowspan="2" valign="top" align="center" style="border-top: solid thin; border-left: solid thin">Genes</th><th colspan="3" valign="top" align="center" style="border-top: solid thin; border-left: solid thin">RNA-seq cohort<break/>HIV-negative TBM (n=207)</th><th colspan="3" valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin">qPCR validation cohort<break/>HIV-negative TBM (n=132)</th></tr><tr><th valign="top" align="center" style="border-top:solid thin; border-left:solid thin">HR</th><th valign="top" align="center" style="border-top:solid thin; border-left:solid thin">95%CI</th><th valign="top" align="center" style="border-top:solid thin; border-left:solid thin">p value</th><th valign="top" align="center" style="border-top:solid thin; border-left:solid thin">HR</th><th valign="top" align="center" style="border-top:solid thin; border-left:solid thin">95%CI</th><th valign="top" align="center" style="border:solid thin">p value</th></tr></thead><tbody><tr><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">1</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">MCEMP1</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">1.93</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">2.37, 1.57</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">4.07E-10</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">1.74</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">2.37, 1.27</td><td valign="top" align="center" style="border:solid thin">4.99E-04</td></tr><tr><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">2</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">FCAR</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">2.37</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">3.30, 1.70</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">3.52E-07</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.59</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.87, 0.40</td><td valign="top" align="center" style="border:solid thin">7.87E-03</td></tr><tr><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">3</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">ETS2</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">2.65</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">3.81, 1.85</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">1.24E-07</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.27</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.44, 0.16</td><td valign="top" align="center" style="border:solid thin">3.27E-07</td></tr><tr><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">4</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">PGD</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">2.65</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">3.81, 1.84</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">1.47E-07</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.18</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.34, 0.09</td><td valign="top" align="center" style="border:solid thin">2.69E-07</td></tr><tr><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">5</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">NELL2</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.56</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.71, 0.45</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">6.08E-07</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.80</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.96, 0.66</td><td valign="top" align="center" style="border:solid thin">1.53E-02</td></tr><tr><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">6</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">TRABD2A</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.43</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.58, 0.31</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">4.94E-08</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.64</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.8, 0.51</td><td valign="top" align="center" style="border:solid thin">1.05E-04</td></tr><tr><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">7</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">TRAF5</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.31</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.49, 0.2</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">4.52E-07</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.47</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.61, 0.36</td><td valign="top" align="center" style="border:solid thin">1.66E-08</td></tr><tr><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">8</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">CD28</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.57</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.76, 0.42</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">1.42E-04</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.60</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.76, 0.47</td><td valign="top" align="center" style="border:solid thin">2.83E-05</td></tr><tr><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">9</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">TESPA1</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.36</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.52, 0.25</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">2.74E-08</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.65</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.89, 0.48</td><td valign="top" align="center" style="border:solid thin">7.35E-03</td></tr><tr><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">10</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">ABLIM1</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.31</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.49, 0.2</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">2.21E-07</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.47</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.63, 0.36</td><td valign="top" align="center" style="border:solid thin">1.55E-07</td></tr><tr><td valign="top" align="center" style="border:solid thin">11</td><td valign="top" align="center" style="border:solid thin">RASGRP1</td><td valign="top" align="center" style="border:solid thin">0.45</td><td valign="top" align="center" style="border:solid thin">0.67, 0.31</td><td valign="top" align="center" style="border:solid thin">6.10E-05</td><td valign="top" align="center" style="border:solid thin">0.59</td><td valign="top" align="center" style="border:solid thin">0.77, 0.45</td><td valign="top" align="center" style="border:solid thin">9.77E-05</td></tr></tbody></table><table-wrap-foot><fn id="TFN8"><p id="P72">Association of the hub genes with three-month mortality using a univariate Cox regression model. Hazard ratio (HR), 95% CI of HR and p-value from the Cox regression model were presented in the table. HR or 95% mean per increase 1 unit of log2 normalized expression of gene in RNA-seq cohort or decrease 1 unit of cycle threshold in qPCR validation cohort.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><title>Comparison of gene signatures in distinguishing survival and death in TBM prognostic models</title></caption><table frame="box" rules="groups"><thead><tr><th colspan="8" valign="middle" align="center" style="border:solid thin">A. RNA-seq cohorts</th></tr><tr><th rowspan="2" valign="top" align="center" style="border-top:solid thin; border-left:solid thin">No.</th><th rowspan="2" valign="middle" align="center" style="border-top:solid thin; border-left:solid thin">Predictor set</th><th colspan="2" valign="top" align="center" style="border-top:solid thin; border-left:solid thin">All TBM n=281</th><th colspan="2" valign="top" align="center" style="border-top:solid thin; border-left:solid thin">HIV-negative TBM n=207</th><th colspan="2" valign="top" align="center" style="border:solid thin">HIV-positive TBM n=74</th></tr><tr><th valign="top" align="center" style="border-top: solid thin; border-left: solid thin">AUC</th><th valign="top" align="center" style="border-top: solid thin; border-left: solid thin">Brier score</th><th valign="top" align="center" style="border-top: solid thin; border-left: solid thin">AUC</th><th valign="top" align="center" style="border-top: solid thin; border-left: solid thin">Brier score</th><th valign="top" align="center" style="border-top: solid thin; border-left: solid thin">AUC</th><th valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin">Brier score</th></tr></thead><tbody><tr><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">1</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin"><bold>Reference model </bold>(PMID: 29029055)</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.78</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.14</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.77</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.12</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin">0.82</td><td valign="top" align="center" style="border-top:solid thin; border-left:solid thin; border-right:solid thin">0.18</td></tr><tr><td valign="top" align="center" style="border-left:solid thin">2</td><td valign="top" align="center" style="border-left:solid thin"><bold>Gene set 1 </bold>(MCEMP1, TRABD2A, and CD4)</td><td valign="top" align="center" style="border-left:solid thin">0.78</td><td valign="top" align="center" style="border-left:solid thin">0.14</td><td valign="top" align="center" style="border-left:solid thin">0.78</td><td valign="top" align="center" style="border-left:solid thin">0.11</td><td valign="top" align="center" style="border-left:solid thin">0.65</td><td valign="top" align="center" style="border-left:solid thin; border-right:solid thin">0.23</td></tr><tr><td valign="top" align="center" style="border-left:solid thin">3</td><td valign="top" align="center" style="border-left:solid thin"><bold>Gene set 2 </bold>(MCEMP1, NELL2 and ZNF354C)</td><td valign="top" align="center" style="border-left:solid thin">0.78</td><td valign="top" align="center" style="border-left:solid thin">0.14</td><td valign="top" align="center" style="border-left:solid thin">0.77</td><td valign="top" align="center" style="border-left:solid thin">0.11</td><td valign="top" align="center" style="border-left:solid thin">0.75</td><td valign="top" align="center" style="border-left:solid thin; border-right:solid thin">0.20</td></tr><tr><td valign="top" align="center" style="border-left:solid thin">4</td><td valign="top" align="center" style="border-left:solid thin"><bold>Gene set 3 </bold>(MCEMP1, TRABD2A, CD4 and ZNF354C)</td><td valign="top" align="center" style="border-left:solid thin">0.78</td><td valign="top" align="center" style="border-left:solid thin">0.14</td><td valign="top" align="center" style="border-left:solid thin">0.77</td><td valign="top" align="center" style="border-left:solid thin">0.11</td><td valign="top" align="center" style="border-left:solid thin">0.73</td><td valign="top" align="center" style="border-left:solid thin; border-right:solid thin">0.21</td></tr><tr><td valign="top" align="center" style="border-left:solid thin">5</td><td valign="top" align="center" style="border-left:solid thin"><bold>Gene set 4 </bold>(MCEMP1, NELL2, CD4 and ZNF354C)</td><td valign="top" align="center" style="border-left:solid thin">0.79</td><td valign="top" align="center" style="border-left:solid thin">0.14</td><td valign="top" align="center" style="border-left:solid thin">0.77</td><td valign="top" align="center" style="border-left:solid thin">0.11</td><td valign="top" align="center" style="border-left:solid thin">0.75</td><td valign="top" align="center" style="border-left:solid thin; border-right:solid thin">0.20</td></tr><tr><td valign="top" align="center" style="border-left:solid thin">6</td><td valign="top" align="center" style="border-left:solid thin"><bold>Gene set 3</bold> and clinical risk factors</td><td valign="top" align="center" style="border-left:solid thin">0.82</td><td valign="top" align="center" style="border-left:solid thin">0.13</td><td valign="top" align="center" style="border-left:solid thin">0.80</td><td valign="top" align="center" style="border-left:solid thin">0.11</td><td valign="top" align="center" style="border-left:solid thin">0.84</td><td valign="top" align="center" style="border-left:solid thin; border-right:solid thin">0.15</td></tr><tr><td valign="top" align="center" style="border-left:solid thin">7</td><td valign="top" align="center" style="border-left:solid thin"><bold>Gene set 4</bold> and clinical risk factors</td><td valign="top" align="center" style="border-left:solid thin">0.82</td><td valign="top" align="center" style="border-left:solid thin">0.13</td><td valign="top" align="center" style="border-left:solid thin">0.80</td><td valign="top" align="center" style="border-left:solid thin">0.11</td><td valign="top" align="center" style="border-left:solid thin">0.86</td><td valign="top" align="center" style="border-left:solid thin; border-right:solid thin">0.14</td></tr><tr><td colspan="8" valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin"><bold>B. qPCR validation cohort</bold></td></tr><tr><td rowspan="2" valign="top" align="center" style="border-top: solid thin; border-left: 1px solid #000000"><bold>No.</bold></td><td rowspan="2" valign="middle" align="center" style="border-top: solid thin; border-left: 1px solid #000000"><bold>Predictor set</bold></td><td colspan="6" valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin"><bold>HIV-negative TBM (n=132)</bold></td></tr><tr><td colspan="3" valign="top" align="center" style="border-top: solid thin; border-left: solid thin"><bold>AUC</bold></td><td colspan="3" valign="top" align="center" style="border-top: solid thin; border-right: solid thin; border-left: solid thin"><bold>Brier score</bold></td></tr><tr><td valign="top" align="center" style="border-top: solid thin; border-bottom: solid thin; border-left: solid thin">8<xref ref-type="table-fn" rid="TFN10">*</xref></td><td valign="top" align="center" style="border-top: solid thin; border-bottom: solid thin; border-left: solid thin">MCEMP1, NELL2, ZNF354C and clinical predictors</td><td colspan="3" valign="top" align="center" style="border-top: solid thin; border-bottom: solid thin; border-left: solid thin">0.92</td><td colspan="3" valign="top" align="center" style="border: solid thin">0.12</td></tr></tbody></table><table-wrap-foot><fn id="TFN9"><p id="P73">Clinical risk factors were age, MRC grade and CSF lymphocytes <sup><xref ref-type="bibr" rid="R14">14</xref></sup>. The prediction models for three-month mortality were based on multivariable logistic regression models with top-hit genes and clinical risk factors. Area under the curve (AUC) and Brier score were corrected for optimism using internal bootstrap resampling over 1,000 iterations to evaluate the model performance. The Brier score is an overall performance measure, calculated as the mean squared difference between the predicted probability and the actual outcome, with smaller values indicating superior model performance.</p></fn><fn id="TFN10"><label>*</label><p id="P74">CD4 data is unavailable for the analysis.</p></fn></table-wrap-foot></table-wrap></floats-group></article>